$258.92
+8.59 (+3.43%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ABBV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 384 interventional · 116 observational · 68 with posted results
Held by 22 tracked-famous managers (CITADEL ADVISORS LLC, MARSHALL WACE, LLP, D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, Man Group plc, +17 more) · FINRA short interest 4.0 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 8 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantNCT07095452Phase 2 and 3: Percentage of Participants with Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Etentamig, Lenalidomide, Daratumumab, Dexamethasone, Dexamethasone | Multiple Myeloma | 660 | Jan 2042 | ≤ 5,644 d | 2026-06-11 |
| Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06896916Phase 1: Dose-Limiting Toxicities (DLT)s of Etentamig when given in Combination with Iberdomide in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Etentamig, Iberdomide | Multiple Myeloma | 135 | Mar 2036 | ≤ 3,512 d | 2026-05-12 |
| Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During PregnancyNCT05158894observationalMajor Congenital Malformations (MCMs) | — | Recruiting | — | Migraine | 1,884 | Jan 2036 | ≤ 3,452 d | 2025-12-15 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsNCT06892522Number of Participants with Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Dexamethasone, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001 | Multiple Myeloma | 602 | Dec 2035 | ≤ 3,421 d | 2026-07-21 |
| A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisNCT07071519PK Lead-In Cohort 1: Maximum Observed Serum Concentration (Cmax)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Risankizumab, Risankizumab | Ulcerative Colitis | 120 | Jul 2034 | ≤ 2,903 d | 2026-08-18 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple MyelomaNCT05259839Number of Participants with Dose Limiting Toxicities (DLT) of EtentamigNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab | Relapsed/Refractory Multiple Myeloma | 283 | Sep 2033 | ≤ 2,599 d | 2026-08-14 |
| Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT07007065Annualized intravitreal anti-VEGF injection rateRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control | Neovascular Age-related Macular Degeneration | 561 | Mar 2033 | ≤ 2,416 d | 2026-08-14 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNCT07728188Safety Run-In: Number of Participants With Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab | Relapsed or Refractory Multiple Myeloma | 520 | Feb 2033 | ≤ 2,385 d | 2026-07-27 |
| A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)NCT04880876Percentage of Participants with Adverse EventsNon-randomized · Quadruple-masked · Treatment | Phase 3 | Enrolling by invitation | Drug: 25mg Eluxadoline, 100mg Eluxadoline | Irritable Bowel Syndrome | 124 | Dec 2032 | ≤ 2,326 d | 2025-07-17 |
| Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved IndicationsNCT04846959observationalNumber of Participants with Major Congenital Malformation (MCM) | — | Recruiting | Drug: Risankizumab, Comparator | Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment | 818 | Jun 2032 | ≤ 2,142 d | 2025-07-17 |
| A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)NCT07581002Phase 2: Complete remission (CR)Randomized · Double-masked · Treatment | Phase 2/3 | Recruiting | Drug: Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK | Acute Myeloid Leukemia | 660 | May 2032 | ≤ 2,112 d | 2026-08-14 |
| Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigraineNCT05707949Percentage of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 3 | Enrolling by invitation | Drug: Atogepant | Migraine Prophylaxis | 650 | Apr 2032 | ≤ 2,081 d | 2025-08-11 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataNCT07772492Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20, defined as less than or equal to 20% scalp hair loss.Randomized · Triple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Upadacitinib, Placebo | Severe Alopecia Areata | 300 | Mar 2032 | ≤ 2,051 d | 2026-08-19 |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102Stage 1: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed | Non-Squamous Non-Small Cell Lung Cancer | 854 | Dec 2031 | ≤ 1,960 d | 2026-06-08 |
| A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)NCT07409246Number of Participants With Adverse Events (AE)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ABBV-438 | Multiple Myeloma | 127 | Nov 2031 | ≤ 1,929 d | 2026-08-14 |
| Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06236438Stage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin, Carboplatin | Non-Small Cell Lung Cancer | 840 | Oct 2031 | ≤ 1,899 d | 2026-02-23 |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisNCT07697456Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic RemissionRandomized · Double-masked · Treatment | Phase 2 | Not yet recruiting | Drug: Risankizumab, Trosunilimab, ABBV-701 | Crohn's Disease, Ulcerative Colitis | 2,000 | Oct 2031 | ≤ 1,899 d | 2026-07-13 |
| Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular LymphomaNCT06830759observationalPercentage of Participants Achieving Overall Response (OR) | — | Recruiting | — | Diffuse Large B-cell Lymphoma, Follicular Lymphoma | 700 | Sep 2031 | ≤ 1,868 d | 2026-02-17 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World SettingNCT07687602observationalNumber of Participants With Adverse Events (AE)s | — | Not yet recruiting | — | Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer | 69 | Aug 2031 | ≤ 1,838 d | 2026-07-07 |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDNCT05210803Incidences of ocular Adverse Events and any Serious Adverse EventsNon-randomized · Open-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Standard of Care, Ranibizumab | Neovascular Age-Related Macular Degeneration (nAMD) | 116 | Jul 2031 | ≤ 1,807 d | 2026-08-05 |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyNCT05296447Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Standard of Care, Aflibercept | Diabetic Retinopathy, DR | 100 | Jun 2031 | ≤ 1,776 d | 2026-08-05 |
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaNCT07490301Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ Leucovorina, Oxaliplatin, Irinotecan | Metastatic Pancreatic Ductal Adenocarcinoma, PDAC | 900 | Jun 2031 | ≤ 1,776 d | 2026-08-14 |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaNCT03314181Overall Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Dexamethasone, Daratumumab, Venetoclax, Bortezomib | Multiple Myeloma | 156 | May 2031 | ≤ 1,746 d | 2025-08-14 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesNCT05753501Number of Participants with Adverse Events (AE)Randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-101, Venetoclax | Hematologic Cancer | 135 | Mar 2031 | ≤ 1,685 d | 2026-08-06 |
| A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsNCT06810505Number of Participants Experiencing Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Atogepant, Placebo for Atogepant | Chronic Migraine | 420 | Mar 2031 | ≤ 1,685 d | 2026-07-14 |
| Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult ParticipantsNCT06575192Occurrence of at Least One Major Complication related to Breast Reconstruction After Stage 1Open-label · Treatment | Phase 3 | Recruiting | Device: ARTIA Reconstructive Tissue Matrix | Breast Reconstruction | 264 | Feb 2031 | ≤ 1,654 d | 2026-08-06 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT02966756Overall Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 66 | Dec 2030 | ≤ 1,595 d | 2026-08-19 |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingNCT03342144observationalPercentage of Participants Achieving Best Overall Response Rate (ORR) | — | Recruiting | — | Chronic Lymphocytic Leukemia (CLL) | 500 | Dec 2030 | ≤ 1,595 d | 2026-08-14 |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)NCT06953960Dose-Limiting Toxicities (DLT)s of ABBV-453Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: ABBV-453, Daratumumab, Dexamethasone, Pomalidomide | Multiple Myeloma | 199 | Dec 2030 | ≤ 1,595 d | 2026-07-07 |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab AdizutecanNCT07196644Number of Participants with Adverse Events (AE)sOpen-label · Treatment | Phase 2 | Recruiting | Drug: Telisotuzumab Adizutecan | Solid Tumors Harboring MET Amplification | 100 | Dec 2030 | ≤ 1,595 d | 2026-08-14 |
| A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)NCT02130362observationalNumber of treatment-emergent AESI per 100 PYs of infections and malignancies | — | Active, not recruiting | — | Crohn's Disease | 1,446 | Nov 2030 | ≤ 1,564 d | 2025-07-16 |
| A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNCT06628310Progression-Free Survival (PFS) as Assessed by InvestigatorRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | 185 | Oct 2030 | ≤ 1,534 d | 2026-07-21 |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)NCT06109272Stage 1: Best Overall Response (BOR) per InvestigatorRandomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab | Hepatocellular Carcinoma | 660 | Sep 2030 | ≤ 1,503 d | 2025-08-15 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)NCT06858813Number of Participants with Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Lenvatinib, ABBV-324 | Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer | 232 | Sep 2030 | ≤ 1,503 d | 2026-03-25 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07155187Phase 2: Objective Response (OR) Assessed by the Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Telisotuzumab Adizutecan, Standard of Care, Osimertinib | Non-Small Cell Lung Cancer | 490 | Sep 2030 | ≤ 1,503 d | 2026-07-09 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerNCT07365241Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: ABBV-706, Topotecan, Topotecan, Lurbinectedin, Amrubicin | Small Cell Lung Cancer | 531 | Sep 2030 | ≤ 1,503 d | 2026-08-19 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in ChinaNCT05821855Change from Baseline in Intraocular Pressure (IOP)Randomized · Open-label · Treatment | Phase 4 | Active, not recruiting | Device: XEN45 Glaucoma Treatment System · Procedure: Trabeculectomy | Open-angle Glaucoma, OAG | 120 | Jul 2030 | ≤ 1,442 d | 2026-04-28 |
| A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisNCT06461897Percentage of Participants Achieving a 75% Reduction from Baseline in Eczema Area and Severity Index 75 (EASI 75) Score (other than US)Randomized · Single-masked · Treatment | Phase 3 | Recruiting | Drug: Upadacitinib, Dupilumab | Atopic Dermatitis | 675 | Jul 2030 | ≤ 1,442 d | 2026-08-06 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataNCT06012240Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Upadacitinib, Placebo | Alopecia Areata | 1,500 | Apr 2030 | ≤ 1,350 d | 2026-08-03 |
| A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's DiseaseNCT07599670Percentage of Participants Experiencing Adverse Events (AEs)Randomized · Triple-masked · Treatment | Phase 1/2 | Recruiting | Drug: ABBV-1758, Placebo for ABBV-1758, ABBV-1758, Placebo for ABBV-1758 | Alzheimer's Disease | 210 | Apr 2030 | ≤ 1,350 d | 2026-08-14 |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.NCT06890338Objective Response (OR) by Independent Central Review (ICR)Open-label · Treatment | Phase 2 | Recruiting | Drug: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant | 140 | Feb 2030 | ≤ 1,289 d | 2026-08-14 |
| Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative ColitisNCT07136116observationalTo assess the achievement of clinical remission per Partial Adapted Mayo Score of Risankizumab treatment in participants with moderate to severe Ulcerative Colitis (UC) | — | Recruiting | — | Ulcerative Colitis | 200 | Feb 2030 | ≤ 1,289 d | 2026-08-14 |
| Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseNCT06548542Percentage of Participants who Achieve Endoscopic RemissionRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Risankizumab, Lutikizumab, Trosunilimab, Risankizumab, Trosunilimab, ABBV-8736 | Crohn's Disease | 540 | Jan 2030 | ≤ 1,261 d | 2026-06-26 |
| A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsNCT07756645Progression-Free Survival (PFS) assessed by the Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: ABBV-1480, Pembrolizumab, Carboplatin, Paclitaxel, Nab- Paclitaxel | Non-Small Cell Lung Cancer | 940 | Dec 2029 | ≤ 1,230 d | 2026-08-11 |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of DiseaseNCT07023289Percentage of Participants with disease free survival (DFS) EventNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Telisotuzumab Adizutecan, Standard of Care | Colorectal Cancer | 140 | Nov 2029 | ≤ 1,199 d | 2026-07-10 |
| A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne ScarsNCT07207369Percentage of Participants who Achieve a 20% Reduction in Acne Scar AreaRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Device: ELAPR002f Injectable Gel, Saline Control | Acne Scars | 395 | Nov 2029 | ≤ 1,199 d | 2025-11-24 |
| Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationNCT07160179Number of Participants Experiencing Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: ABBV-6628, SYFOVRE | Geographic Atrophy, Age-Related Macular Degeneration | 66 | Oct 2029 | ≤ 1,169 d | 2026-07-13 |
| A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT07744126Number of Participants with Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil | Head and Neck Squamous Cell Carcinoma | 150 | Oct 2029 | ≤ 1,169 d | 2026-08-10 |
| Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in BelgiumNCT06581042observationalPercentage of Participants Achieving Clinical Remission as per Partial Adapted Mayo Subscores for Ulcerative Colitis | — | Recruiting | — | Ulcerative Colitis, Crohn's Disease | 280 | Sep 2029 | ≤ 1,138 d | 2025-03-05 |
| Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary FibrosisNCT07230288Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ABBV-142, Placebo for ABBV-142 | Idiopathic Pulmonary Fibrosis | 165 | Sep 2029 | ≤ 1,138 d | 2026-04-09 |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT05650632Arm A (Part 1 and Part 2) Arm C, and Arm D: Number of Grade >= 2 Cytokine Release Syndrome (CRS) EventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Etentamig (ABBV-383) | Multiple Myeloma | 210 | Aug 2029 | ≤ 1,108 d | 2026-07-13 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsNCT05618028Number of Participants With Adverse Events (AE)Randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-525 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma | 78 | Jul 2029 | ≤ 1,077 d | 2026-05-04 |
| A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face VolumeNCT06734351Percentage of Participants Achieving "Responder" Status Based on the Evaluating Investigator's (EI) Live Assessment of Mid-Face Volume Deficit Scale (MFVDS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Device: NOA VOLUME, VOLUMA XC | Mid Face Volume Deficit | 231 | Jul 2029 | ≤ 1,077 d | 2026-06-18 |
| Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.NCT05609630Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 30 ResponseRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Upadacitinib, Tocilizumab | Juvenile Idiopathic Arthritis | 90 | Jun 2029 | ≤ 1,046 d | 2026-08-14 |
| Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's DiseaseNCT06107426observationalChange From Baseline in OFF Time (hours) | — | Active, not recruiting | — | Parkinson's Disease (PD) | 427 | May 2029 | ≤ 1,016 d | 2026-04-27 |
| Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic MigraineNCT06603558observationalPercentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR) | — | Recruiting | Drug: Atogepant | Chronic Migraine, Episodic Migraine, Migraine | 3,000 | May 2029 | ≤ 1,016 d | 2026-07-22 |
| A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerNCT07525206Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil | Colorectal Cancer | 700 | May 2029 | ≤ 1,016 d | 2026-07-29 |
| AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular HypertensionNCT04499248Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study EyeRandomized · Quadruple-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: AGN-193408 SR, AGN-193408 SR · Other: Lumigan, Sham Administration, Lumigan Vehicle, Sham Administration, Lumigan Vehicle | Open-angle Glaucoma, Ocular Hypertension | 100 | Apr 2029 | ≤ 985 d | 2026-05-22 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseNCT05995353Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical RemissionRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Risankizumab, Risankizumab | Crohn's Disease | 110 | Apr 2029 | ≤ 985 d | 2026-05-29 |
| A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174Number of Participants with Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Carboplatin, Lurbinectedin | Small Cell Lung Cancer | 180 | Apr 2029 | ≤ 985 d | 2026-08-14 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsNCT07241039Number of Participants with Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ABBV-711, Budigalimab | Advanced Squamous Tumors | 220 | Apr 2029 | ≤ 985 d | 2026-08-19 |
| A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)NCT06977724Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ABBV-319 | Dry Eye Syndrome, Systemic Lupus Erythematosus | 36 | Mar 2029 | ≤ 955 d | 2026-08-10 |
| A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseaseNCT03105102Sub-Study 1: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical RemissionRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI) | Crohn's Disease | 1,336 | Feb 2029 | ≤ 924 d | 2026-08-14 |
| Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineNCT06543914observationalPercentage of Participants Achieving a rating of "much better" or "very much better" as assessed by the Patient Global Impression of Change (PGI-C) | — | Active, not recruiting | — | Migraine | 1,314 | Feb 2029 | ≤ 924 d | 2026-06-01 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia AreataNCT07023302Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 10Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Upadacitinib Placebo | Alopecia Areata | 125 | Feb 2029 | ≤ 924 d | 2026-07-30 |
| An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic ArthritisNCT06764693observationalNumber of participants that show persistence in treatment until 24 months | — | Recruiting | — | Psoriatic Arthritis | 1,200 | Jan 2029 | ≤ 896 d | 2026-02-17 |
| A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerNCT07059845Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin | Ovarian Cancer | 400 | Jan 2029 | ≤ 896 d | 2026-08-04 |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian CancerNCT07278336Number of Participants with Adverse Events (AE)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ABBV-901, Bevacizumab | Ovarian Cancer | 219 | Jan 2029 | ≤ 896 d | 2026-07-15 |
| A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07607964Change from Baseline in B Cells in BloodNon-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: ABBV-519, ABBV-519 | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 30 | Jan 2029 | ≤ 896 d | 2026-07-01 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic ArthritisNCT03725007Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Upadacitinib | Juvenile Idiopathic Arthritis (JIA) | 124 | Dec 2028 | ≤ 865 d | 2026-08-03 |
| Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyNCT03999801Incidence of ocular adverse events and any serious adverse events in the study eyeNon-randomized · Open-label · Treatment | Phase 2 | Enrolling by invitation | Genetic: RGX-314 | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | 865 | Dec 2028 | ≤ 865 d | 2024-06-17 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: Telisotuzumab Vedotin · Drug: Docetaxel | Non Small Cell Lung Cancer | 768 | Dec 2028 | ≤ 865 d | 2026-07-28 |
| A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettINGNCT06712628observationalRetention Rate of UPA vs TNFi | — | Recruiting | — | Moderate to Severe Rheumatoid Arthritis | 678 | Dec 2028 | ≤ 865 d | 2026-07-30 |
| A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With GlaucomaNCT06822738Percentage of Participants With Treatment Response of Achieving ≥ 20% Reduction in Intraocular Pressure (IOP) From Baseline on the Same or Fewer Number of IOP-Lowering Medications Compared to BaselineSingle-masked · Treatment | Phase 3 | Recruiting | Device: XEN63 Glaucoma Treatment System | Primary Open Angle Glaucoma | 130 | Nov 2028 | ≤ 834 d | 2026-08-14 |
| Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential TremorNCT07673107Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS)Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: AGN-151607-DP, Placebo for AGN-151607-DP | Upper Limb Essential Tremor | 94 | Nov 2028 | ≤ 834 d | 2026-06-29 |
| A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersNCT07769502Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel | Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma | 168 | Nov 2028 | ≤ 834 d | 2026-08-18 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative ColitisNCT03398135Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo ScoreRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: risankizumab, placebo for risankizumab | Ulcerative Colitis (UC) | 1,242 | Sep 2028 | ≤ 773 d | 2026-01-20 |
| Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.NCT05930275observationalTime to Achieve First Clinical Response (CR) per Patient-Reported Outcome 2 (PRO2) (Daily CR-PRO) | — | Active, not recruiting | — | Crohn's Disease | 1,200 | Sep 2028 | ≤ 773 d | 2025-07-17 |
| Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia RepairNCT07226791Percentage of Participants Achieving Primary Fascial Closure (PFC) Without Use of Component Separation Technique (CST) in Open Ventral Hernia Surgical RepairRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: AGN-151607-DP, Placebo for AGN-151607-DP | Ventral Hernia | 200 | Sep 2028 | ≤ 773 d | 2026-08-18 |
| A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in BelgiumNCT07382440observationalChange From Baseline in OFF Time (hours) as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV | — | Recruiting | — | Parkinson's Disease | 120 | Sep 2028 | ≤ 773 d | 2026-07-10 |
| A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)NCT04161898Time to First Relapse of Takayasu Arteritis (TAK) From Baseline through End of the Double-Blind (DB) PeriodRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo for Upadacitinib, Prednisolone | Takayasu Arteritis (TAK) | 56 | Aug 2028 | ≤ 743 d | 2026-02-18 |
| Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.NCT05782907Percentage of Participants Achieving Adapted Mayo score (AMS) Clinical Remission (Period 1)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib | Ulcerative Colitis | 122 | Aug 2028 | ≤ 743 d | 2026-05-14 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)NCT05841537observationalPercentage of Participants with Clinical Remission among Participants with Clinical Response at Month 3 | — | Active, not recruiting | — | Crohn's Disease | 1,019 | Jul 2028 | ≤ 712 d | 2025-05-09 |
| Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative ColitisNCT06764706observationalPercentage of Participants Achieving Symptomatic Remission Responder Per Partial Adapted Mayo Score | — | Recruiting | — | Ulcerative Colitis | 200 | Jul 2028 | ≤ 712 d | 2026-06-18 |
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)NCT07387471Number of Participants with Major ResponseOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: Venetoclax | Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | 16 | Jul 2028 | ≤ 712 d | 2026-07-31 |
| Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)NCT07741838observationalPercentage of Participants Achieving Minimal Disease Activity (MDA) | — | Not yet recruiting | — | Atopic Dermatitis | 900 | Jul 2028 | ≤ 712 d | 2026-08-03 |
| A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)NCT01848561observationalEvaluation of long term safety of Adalimumab in patients with moderately to severely active UC | — | Active, not recruiting | — | Ulcerative Colitis (UC) | 8,250 | Jun 2028 | ≤ 681 d | 2025-07-16 |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaNCT07592273Phase 2B: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study EyeRandomized · Double-masked · Treatment | Phase 2/3 | Recruiting | Drug: Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears | Diabetic Retinopathy | 576 | Jun 2028 | ≤ 681 d | 2026-08-14 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977NCT04862286Number of Participants With Adverse EventsOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Risankizumab | Psoriasis | 132 | Apr 2028 | ≤ 620 d | 2025-08-12 |
| A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)NCT07306832Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment DiscontinuationNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Pivekimab Sunirine | Acute Myeloid Leukemia | 18 | Apr 2028 | ≤ 620 d | 2026-08-14 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World PracticeNCT05494606observationalMedian Time to Achieve the First Clinical Response (CR) per Partial Adapted Mayo Score | — | Active, not recruiting | — | Ulcerative Colitis | 785 | Mar 2028 | ≤ 590 d | 2025-02-28 |
| A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineNCT05711394Change from Baseline in Mean Monthly Migraine DaysRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Atogepant, Placebo-Matching Atogepant | Episodic Migraine | 450 | Mar 2028 | ≤ 590 d | 2026-08-14 |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyNCT05889182Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 50Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo | Hidradenitis Suppurativa | 1,328 | Mar 2028 | ≤ 590 d | 2026-08-14 |
| A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With VitiligoNCT06118411Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo · Other: NB-UVB (narrow-band ultraviolet B) Phototherapy | Vitiligo | 614 | Mar 2028 | ≤ 590 d | 2026-06-09 |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)NCT06428019Part 1: Percentage of Participants with Treatment-Emergent Laboratory Tumor Lysis Syndrome (TLS)-VenetoclaxRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Venetoclax, Acalabrutinib, Obinutuzumab | Chronic Lymphocytic Leukemia | 170 | Mar 2028 | ≤ 590 d | 2026-04-09 |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerNCT06820463Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Panitumumab | Metastatic Colorectal Cancer | 390 | Mar 2028 | ≤ 590 d | 2026-08-14 |
| Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT07039110observationalProportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1 | — | Recruiting | — | Plaque Psoriasis | 700 | Mar 2028 | ≤ 590 d | 2026-08-05 |
| Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United KingdomNCT07690215observationalPercentage of Participants Achieving a Rating of "Much Better" or "Very Much Better" Following Atogepant Initiation As Assessed by Patient's Global Impression of Change (PGI-C) | — | Not yet recruiting | — | Migraine | 200 | Mar 2028 | ≤ 590 d | 2026-07-08 |
| Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979Percent Change From Baseline in Body WeightRandomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: ABBV-295, Placebo | Obesity, Overweight | 360 | Mar 2028 | ≤ 590 d | 2026-08-07 |
| Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)NCT04524611Percentage of Participants Achieving Clinical Remission at Week 24Randomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Risankizumab, Risankizumab, Ustekinumab, Ustekinumab | Crohn's Disease (CD) | 527 | Feb 2028 | ≤ 559 d | 2026-04-13 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) InfusionNCT06158854Dose Escalation Only: Number of Participants with Dose-Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: ABBV-383 (Etentamig) | Immunoglobulin Light Chain (AL) Amyloidosis | 76 | Feb 2028 | ≤ 559 d | 2026-05-13 |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06568939Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Telisotuzumab Vedotin | Non-Small Cell Lung Cancer | 150 | Feb 2028 | ≤ 559 d | 2026-08-14 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaNCT07145918Number of Participants with Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Emraclidine, Placebo | Schizophrenia | 268 | Feb 2028 | ≤ 559 d | 2026-02-10 |
| A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult ParticipantsNCT07673120Number of Participants with Adverse Events (AEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Recruiting | Drug: ABBV-313, Placebo, ABBV-313, Placebo | Healthy Volunteers | 64 | Feb 2028 | ≤ 559 d | 2026-07-24 |
| Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)NCT05127954Percentage of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 3 | Enrolling by invitation | Drug: Ubrogepant | Migraine | 1,200 | Jan 2028 | ≤ 530 d | 2025-07-20 |
| A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesNCT07024784Number of Participants With Dose-limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: IMGN151, Carboplatin, Bevacizumab, Olaparib | Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC) | 377 | Jan 2028 | ≤ 530 d | 2026-06-02 |
| A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic TherapyNCT05139602Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR)Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Biological: Lutikizumab · Drug: Placebo | Hidradenitis Suppurativa | 210 | Dec 2027 | ≤ 499 d | 2026-02-13 |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06158841Progression Free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone | Multiple Myeloma | 380 | Dec 2027 | ≤ 499 d | 2026-08-03 |
| Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal CancerNCT06464692Dose-Limiting Toxicity (DLT) of Telisotuzumab Adizutecan in Stage 1Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Telisotuzumab Adizutecan | Colorectal Cancer | 31 | Dec 2027 | ≤ 499 d | 2026-05-11 |
| Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisNCT06865105Percentage of Participants With an American College of Rheumatology 50% (ACR50) ResponseRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Lutikizumab, Risankizumab | Psoriatic Arthritis | 120 | Dec 2027 | ≤ 499 d | 2025-12-18 |
| A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World SettingNCT07073079observationalPercentage of Participants who Achieve Corticosteroids (CS) Free Remission | — | Recruiting | — | Crohn's Disease | 250 | Dec 2027 | ≤ 499 d | 2026-06-24 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabNCT05029882Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-400, Trifluridine/Tipiracil, Bevacizumab | Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer | 520 | Nov 2027 | ≤ 468 d | 2025-10-29 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsNCT05599984Percentage of Participants With Adverse Events (AE)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-706, Cisplatin, Budigalimab, Carboplatin | Advanced Solid Tumors | 288 | Nov 2027 | ≤ 468 d | 2026-05-07 |
| Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06417775Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment PeriodRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ubrogepant, Placebo for Ubrogepant | Migraine | 496 | Nov 2027 | ≤ 468 d | 2026-08-14 |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderNCT06696755Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Icalcaprant, Placebo for Icalcaprant | Bipolar I Disorder, Bipolar II Disorder | 195 | Nov 2027 | ≤ 468 d | 2026-08-14 |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab AdizutecanRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin | Non Small Cell Lung Carcinoma | 252 | Nov 2027 | ≤ 468 d | 2026-08-14 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in IndiaNCT07044687Percentage of Participants with Treatment Emergent Adverse Events (TEAE)sOpen-label · Treatment | Phase 4 | Recruiting | Drug: Venetoclax, Azacitidine, Azacitidine | Acute Myeloid Leukemia | 100 | Nov 2027 | ≤ 468 d | 2026-08-14 |
| Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in GreeceNCT06247319observationalProportion of participants achieving Psoriasis Area and Severity Index (PASI) score less than or equal to 2 | — | Active, not recruiting | — | Moderate Plaque Psoriasis, Moderate Psoriasis, Psoriasis | 250 | Oct 2027 | ≤ 438 d | 2026-02-04 |
| Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson DiseaseNCT07227896observationalChange From Baseline in OFF Time (hours) as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV | — | Not yet recruiting | — | Parkinson's Disease | 100 | Oct 2027 | ≤ 438 d | 2026-02-17 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433NCT03345823Sub-Study 1: Percentage of Participants with Clinical Remission per Crohn's Disease Activity Index (CDAI)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo for Upadacitinib | Crohn's Disease | 747 | Sep 2027 | ≤ 407 d | 2026-04-09 |
| A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World SettingNCT05139836observationalPercentage of Participants Achieving Disease Control Defined by Atopic Dermatitis Control Tool (ADCT) Total Score <7 Points | — | Active, not recruiting | — | Atopic Dermatitis | 634 | Sep 2027 | ≤ 407 d | 2026-08-14 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-400, Itraconazole (ITZ), Bevacizumab | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | 302 | Sep 2027 | ≤ 407 d | 2026-08-04 |
| A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisNCT06257875Percentage of Participants who Achieve Endoscopic ImprovementRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Lutikizumab, Lutikizumab, Adalimumab | Ulcerative Colitis | 156 | Sep 2027 | ≤ 407 d | 2025-10-07 |
| A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult ParticipantsNCT06345339Percentage of Participants who Achieve Thyroid-Stimulating Hormone (TSH) ResponseRandomized · Triple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Armour Thyroid, Levothyroxine | Hypothyroidism | 2,800 | Sep 2027 | ≤ 407 d | 2026-01-05 |
| Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)NCT06916507observationalChange From Baseline in OFF Time (hours) | — | Recruiting | — | Parkinson's Disease | 125 | Sep 2027 | ≤ 407 d | 2026-05-28 |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderNCT07276997Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Icalcaprant, Placebo for Icalcaprant | Major Depressive Disorder | 195 | Sep 2027 | ≤ 407 d | 2026-06-15 |
| An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialNCT03844048Number of Participants With Adverse EventsOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer | 165 | Aug 2027 | ≤ 377 d | 2026-05-13 |
| Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative ColitisNCT05496348observationalPercentage of participants achieving symptomatic remission per partial adapted Mayo score among those who achieved clinical response and/or intestinal ultrasound (IUS) response at week 8 of upadacitinib (UPA) induction | — | Active, not recruiting | — | Ulcerative Colitis | 400 | Aug 2027 | ≤ 377 d | 2026-07-16 |
| A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal CancerNCT06614192Percentage of Participants with Adverse Events (AE)sRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Telisotuzumab Adizutecan | Metastatic Colorectal Cancer | 74 | Aug 2027 | ≤ 377 d | 2026-05-28 |
| A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabNCT06880744Percentage of Risankizumab Group Participants Achieving Endoscopic Improvement As Compared to The Vedolizumab GroupRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Risankizumab, Risankizumab, Vedolizumab | Ulcerative Colitis | 573 | Aug 2027 | ≤ 377 d | 2026-08-04 |
| A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis SuppurativaNCT07136467observationalAlopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only | — | Recruiting | — | Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa | 2,795 | Aug 2027 | ≤ 377 d | 2026-02-13 |
| A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 InjectionsNCT07232004Number of Participants with Adverse Events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-547, ABBV-547 Placebo | Healthy Volunteer | 121 | Aug 2027 | ≤ 377 d | 2026-07-24 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)NCT03006068Assessing Treatment-Emergent Adverse EventsNon-randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib (ABT-494), Placebo | Ulcerative Colitis (UC) | 950 | Jul 2027 | ≤ 346 d | 2026-01-12 |
| A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)NCT03987958observationalOverall Survival | — | Active, not recruiting | — | Acute Myeloid Leukemia | 100 | Jul 2027 | ≤ 346 d | 2026-01-16 |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainNCT04333576Percentage of Responders Based on Dysmenorrhea (DYS) Pain ScaleRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Elagolix, Placebo, Combined Oral Contraceptive | Endometriosis | 800 | Jul 2027 | ≤ 346 d | 2026-06-12 |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeNCT04401748Overall survival (OS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Venetoclax, Azacitidine, Placebo | Myelodysplastic Syndrome (MDS) | 531 | Jul 2027 | ≤ 346 d | 2026-05-06 |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403Number of Participants with Adverse Events (AE)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan | Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer | 694 | Jul 2027 | ≤ 346 d | 2026-06-23 |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT06291220Percentage of Participants With Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Obinutuzumab, ABBV-453 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 4 | Jul 2027 | ≤ 346 d | 2026-01-08 |
| Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)NCT02899052Number of Participants with Adverse EventsOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: Carfilzomib, Venetoclax, Dexamethasone | Multiple Myeloma | 120 | Jun 2027 | ≤ 315 d | 2025-08-05 |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsNCT03821935Dose Escalation: Recommended Phase 2 Dose (RP2D) Livmoniplimab MonotherapyRandomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Livmoniplimab, Budigalimab | Advanced Solid Tumors Cancer | 364 | Jun 2027 | ≤ 315 d | 2025-05-25 |
| Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseNCT06332534Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Upadacitinib | Crohn's Disease | 110 | Jun 2027 | ≤ 315 d | 2026-06-24 |
| Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson DiseaseNCT06965374observationalChange From Baseline in Quality of Life as Measured by PD Questionnaire-39 (PDQ-39) Summary Index | — | Recruiting | — | Parkinson Disease | 270 | Jun 2027 | ≤ 315 d | 2026-05-13 |
| Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)NCT05125302Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 yearsRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Ubrogepant, Placebo-Matching Ubrogepant | Migraine | 1,059 | May 2027 | ≤ 285 d | 2026-07-30 |
| A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273Percentage of Participants With Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-969 | Metastatic Castration-Resistant Prostate Cancer | 152 | May 2027 | ≤ 285 d | 2026-06-17 |
| A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisNCT06718101Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Lutikizumab, Placebo | Atopic Dermatitis | 83 | May 2027 | ≤ 285 d | 2026-08-14 |
| A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.NCT07306754Number of Participants with Adverse Events (AEs)Randomized · Double-masked · Basic science | Phase 1 | Recruiting | Drug: ABBV-243, Placebo, ABBV-243, Placebo | Healthy Volunteers | 66 | May 2027 | ≤ 285 d | 2026-01-12 |
| A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world SettingNCT05094128observationalPercentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score Low Disease Activity (ASDAS LDA [< 2.1]) | — | Active, not recruiting | Drug: Upadacitinib | Axial Spondylarthritis (r-axSpA) | 338 | Apr 2027 | ≤ 254 d | 2026-05-26 |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerNCT05445778Assess Progression-free survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 520 | Apr 2027 | ≤ 254 d | 2026-06-02 |
| A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in ChinaNCT06548568observationalNumber of Participants with Treatment Emergent Adverse Events (TEAEs), including Adverse Events of Special Interest (AESIs) | — | Active, not recruiting | — | Diabetic Macular Edema | 110 | Apr 2027 | ≤ 254 d | 2025-09-19 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaNCT06667687Percentage of Participants with Adverse Events (AE)sNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-291 | Non-Hodgkin's Lymphoma | 21 | Apr 2027 | ≤ 254 d | 2026-08-14 |
| Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II DisorderNCT07220460Number of Participants Experiencing Adverse EventsOpen-label · Treatment | Phase 2 | Recruiting | Drug: ABBV-932 | Bipolar I or II Disorder | 200 | Apr 2027 | ≤ 254 d | 2026-06-18 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult ParticipantsNCT07570147Number of Participants with Adverse Events (AEs)Randomized · Double-masked · Basic science | Phase 1 | Recruiting | Drug: ABBV-1451, ABBV-1451 · Other: Placebo, Placebo | Healthy Volunteer | 90 | Apr 2027 | ≤ 254 d | 2026-05-28 |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.NCT04777357Number of Participants with Adverse EventsRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Cariprazine, Placebo | Depression, Bipolar I Disorder | 380 | Mar 2027 | ≤ 224 d | 2026-07-27 |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in CanadaNCT05424562observationalOverall Survival (OS) | — | Active, not recruiting | — | Acute Myeloid Leukemia | 210 | Mar 2027 | ≤ 224 d | 2025-11-28 |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusNCT05843643Percentage of Participants Achieving British Isles Lupus Assessment Group Based Combined Lupus Assessment (BICLA) ResponseRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo | Systemic Lupus Erythematosus | 1,014 | Mar 2027 | ≤ 224 d | 2026-04-28 |
| A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.NCT06063967Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (CDAI < 150)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Risankizumab SC, Placebo for risankizumab | Crohn's Disease | 289 | Mar 2027 | ≤ 224 d | 2025-09-09 |
| Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)NCT06632951Overall Survival (OS)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Docetaxel, Paclitaxel, Gemcitabine | Urothelial Carcinoma | 150 | Mar 2027 | ≤ 224 d | 2025-08-11 |
| Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life SettingNCT06639620observationalChange From Baseline in Parkinson's Disease Questionnaire-8 (PDQ) total score. | — | Active, not recruiting | — | Advanced Parkinson Disease | 250 | Mar 2027 | ≤ 224 d | 2026-02-27 |
| A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult ParticipantsNCT07219030Number of Participants Experiencing Adverse EventsRandomized · Quadruple-masked · Basic science | Phase 1 | Recruiting | Drug: Emraclidine, Placebo | Healthy Volunteer | 40 | Mar 2027 | ≤ 224 d | 2026-05-12 |
| A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityNCT07291232Number of Participants with Adverse Events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: ABBV-295, Placebo | Obesity | 80 | Mar 2027 | ≤ 224 d | 2026-08-07 |
| Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine AttacksNCT07310290observationalPercentage of Participants with Absence of moderate to severe headache over 24 hours post-dose during prodrome. | — | Recruiting | — | Migraine | 189 | Mar 2027 | ≤ 224 d | 2026-02-10 |
| Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) CountriesNCT07539844observationalFolate Receptor Alpha (FRa) Overexpression Immunohistochemistry (IHC)in Each Participating Sites (Local and Central) | — | Recruiting | — | Ovarian Cancer | 1,000 | Mar 2027 | ≤ 224 d | 2026-07-31 |
| A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular EdemaNCT07604545observationalProportion of participants gaining ≥10 Early treatment diabetic retinopathy study (ETDRS) letters Best Corrected Visual Acuity (BCVA) | — | Not yet recruiting | — | Diabetic Macular Edema | 554 | Mar 2027 | ≤ 224 d | 2026-05-22 |
| A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesNCT07756580Number of Participants with Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: AGN-151586, BOTOX | Glabellar Lines | 120 | Mar 2027 | ≤ 224 d | 2026-08-10 |
| IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaNCT04086264Safety and TolerabilityNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Azacitidine, IMGN632, Venetoclax | Acute Myeloid Leukemia | 218 | Feb 2027 | ≤ 193 d | 2025-08-14 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)NCT05512390Number of Dose-Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ABBV-319 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma | 154 | Feb 2027 | ≤ 193 d | 2026-01-16 |
| First in Human Study of IMGN151 in Recurrent Gynaecological CancersNCT05527184Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: IMGN151 | Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer | 256 | Feb 2027 | ≤ 193 d | 2026-02-20 |
| An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real WorldNCT05669794observationalPercentage of Participants achieving an absolute SCORing Atopic Dermatitis (SCORAD) of <25 | — | Active, not recruiting | — | Atopic Dermatitis | 300 | Feb 2027 | ≤ 193 d | 2025-02-27 |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06223516Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig | Multiple Myeloma | 60 | Feb 2027 | ≤ 193 d | 2026-03-27 |
| A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)NCT06487559Percentage of Participants With Adverse Events (AE)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Livmoniplimab, Budigalimab | Hepatocellular Carcinoma (HCC) | 3 | Feb 2027 | ≤ 193 d | 2026-08-17 |
| A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of LutikizumabNCT06524635Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · Basic science | Phase 2 | Recruiting | Drug: Lutikizumab | Hidradenitis Suppurativa, Atopic Dermatitis | 60 | Feb 2027 | ≤ 193 d | 2025-01-24 |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisNCT06972446Percentage of Participants With an American College of Rheumatology 50% (ACR50) ResponseRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: Lutikizumab, Placebo, Ravagalimab | Rheumatoid Arthritis | 180 | Feb 2027 | ≤ 193 d | 2026-07-10 |
| A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar DisorderNCT07071532Maximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCAROpen-label · Basic science | Phase 1 | Not yet recruiting | Drug: ABBV-932, Itraconazole | Bipolar Disorder | 20 | Feb 2027 | ≤ 193 d | 2026-08-06 |
| A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult ParticipantsNCT07736638Number of Participants with Adverse Events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: ABBV-859, Placebo for ABBV-859, ABBV-859, Placebo for ABBV-859 | Healthy Volunteer | 64 | Feb 2027 | ≤ 193 d | 2026-08-03 |
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisNCT04454658Percentage of Participants With Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-744, Navitoclax, Ruxolitinib | Myelofibrosis (MF) | 21 | Jan 2027 | ≤ 165 d | 2025-07-16 |
| An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's DiseaseNCT05916157observationalPercentage of Participants Experiencing Infusion Site Infections | — | Active, not recruiting | — | Parkinson's Disease (PD) | 250 | Jan 2027 | ≤ 165 d | 2026-05-15 |
| Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisNCT06701331Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Placebo, Upadacitinib | Atopic Dermatitis | 99 | Jan 2027 | ≤ 165 d | 2026-02-23 |
| A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/FoscarbidopaNCT07284342observationalChange from Baseline on Parkinson's Disease (PD)-related sleep disturbances in Advance Parkinson's Disease (aPD) Participants, as assessed by the Parkinson's Disease Sleep Scale - 2 (PDSS-2) | — | Recruiting | — | Advanced Parkinson's Disease | 103 | Jan 2027 | ≤ 165 d | 2026-07-31 |
| A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult ParticipantsNCT07466550Number of Participants with Adverse Events (AEs)Randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: Risankizumab, Risankizumab | Healthy Volunteer | 60 | Jan 2027 | ≤ 165 d | 2026-07-01 |
| A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.NCT07514260Number of Participants with Adverse Events (AEs)Randomized · Triple-masked · Basic science | Phase 1 | Active, not recruiting | Drug: ABBV-295, Placebo for ABBV-295 | Healthy Volunteer | 24 | Jan 2027 | ≤ 165 d | 2026-08-14 |
| Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenNCT03339128Change from baseline in stool consistency averaged over the 4-week Treatment PeriodRandomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Eluxadoline, Placebo | Irritable Bowel Syndrome | 95 | Dec 2026 | ≤ 134 d | 2025-09-19 |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmNCT04041050Number of Participants with Dose Limiting Toxicities (DLT) (Part 1 and Part 2)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Navitoclax, Ruxolitinib, Celecoxib | Myeloproliferative Neoplasm | 85 | 2026-12-31 | in 134 d | 2025-02-14 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDNCT04704921Mean change from baseline in Best Corrected Visual Acuity (BCVA)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Genetic: ABBV-RGX-314, ABBV-RGX-314 · Biological: Ranibizumab (LUCENTIS®) | AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization | 671 | Dec 2026 | ≤ 134 d | 2026-04-28 |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in GreeceNCT05317494observationalPercentage of Participants Achieving Overall Survival (OS) | — | Recruiting | — | Acute Myeloid Leukemia | 100 | Dec 2026 | ≤ 134 d | 2025-07-16 |
| Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal ImplantNCT05978622observationalNumber of Additional Anti-VEGF Injections after Baseline and before DEX-I Initiation | — | Active, not recruiting | — | Diabetic Macular Edema | 236 | Dec 2026 | ≤ 134 d | 2026-05-01 |
| Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabNCT06107413Percentage of Participants with Objective ResponseRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan | Unresectable Metastatic Colorectal Cancer | 280 | Dec 2026 | ≤ 134 d | 2025-12-12 |
| A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT06468228Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Lutikizumab, Placebo | Hidradenitis Suppurativa | 1,400 | Dec 2026 | ≤ 134 d | 2026-08-14 |
| An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)NCT06838845observationalAchievement of clinical response per partial adapted Mayo score. | — | Recruiting | — | Ulcerative Colitis | 80 | Dec 2026 | ≤ 134 d | 2025-11-26 |
| A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigraineNCT06602479Efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraineRandomized · Double-masked · Prevention | Phase 2 | Recruiting | Drug: MEDI0618, Placebo | Migraine | 488 | 2026-12-18 | in 121 d | 2026-05-19 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)NCT04895436Overall response (OR) in Cohort 1 after end of combination treatmentNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Venetoclax, Obinutuzumab | Chronic Lymphocytic Leukemia (CLL) | 75 | Nov 2026 | ≤ 103 d | 2026-02-09 |
| Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerNCT05456685Overall Response Rate (ORR)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Mirvetuximab soravtansine, Carboplatin | High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 125 | Nov 2026 | ≤ 103 d | 2025-10-28 |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaNCT05587049observationalOverall Survival (OS) | — | Recruiting | — | Acute Myeloid Leukemia | 70 | Nov 2026 | ≤ 103 d | 2025-08-08 |
| Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)NCT05822752Best Overall Response (BOR) per InvestigatorRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib | Hepatocellular Carcinoma | 130 | Nov 2026 | ≤ 103 d | 2025-08-14 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in JapanNCT06023030observationalPercentage of Participants with Drug Related Serious Infections | — | Recruiting | — | Crohn's Disease | 240 | Nov 2026 | ≤ 103 d | 2026-02-24 |
| A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in ItalyNCT06058741observationalOverall Survival (OS) | — | Active, not recruiting | — | Acute Myeloid Leukemia | 150 | Nov 2026 | ≤ 103 d | 2025-04-22 |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderNCT06846320Number of Participants with Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT) | Generalized Anxiety Disorder (GAD) | 315 | Nov 2026 | ≤ 103 d | 2026-06-17 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian ParticipantsNCT06895343Number of Participants Experiencing Adverse EventsRandomized · Quadruple-masked · Basic science | Phase 1 | Active, not recruiting | Drug: ABBV-701, Placebo, ABBV-701, Placebo | Healthy Volunteer | 100 | Nov 2026 | ≤ 103 d | 2026-03-02 |
| A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in ItalyNCT07407062observationalFRα - Positive Status | — | Recruiting | — | Cancer - Ovarian | 200 | Nov 2026 | ≤ 103 d | 2026-07-27 |
| A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsNCT07730554Number of Participants with Adverse Events (AEs)Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: AGN-151586 | Forehead Lines | 80 | Nov 2026 | ≤ 103 d | 2026-07-28 |
| A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic DermatitisNCT05081557observationalUpadacitinib (UPA) Utilization Patterns | — | Active, not recruiting | — | Atopic Dermatitis | 873 | Oct 2026 | ≤ 73 d | 2025-08-14 |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDNCT05407636Mean change from baseline in Best Corrected Visual Acuity (BCVA)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 · Biological: Aflibercept (EYLEA®) | AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV | 735 | Oct 2026 | ≤ 73 d | 2026-08-03 |
| Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsNCT07680686Number of Participants Experiencing Adverse EventsRandomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: Ubrogepant, Ubrogepant | Healthy Volunteer | 52 | Oct 2026 | ≤ 73 d | 2026-08-10 |
| A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsNCT02988960Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-927, ABBV-927, ABBV-181 | Advanced Solid Tumors Cancer | 163 | Sep 2026 | ≤ 42 d | 2026-01-09 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabNCT06100744Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30)Randomized · Single-masked · Treatment | Phase 3 | Recruiting | Drug: Adalimumab, Risankizumab | Juvenile Psoriatic Arthritis | 40 | Sep 2026 | ≤ 42 d | 2026-07-31 |
| A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male ParticipantsNCT06953934Maximum Plasma Concentration (Cmax) of ABBV-932Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: ABBV-932 | Healthy Volunteer | 8 | Sep 2026 | ≤ 42 d | 2026-06-29 |
| A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNCT07421258observationalPercentage of Participants Managed Using Treat-to-Target (T2T) | — | Recruiting | — | Crohn's Disease, Ulcerative Colitis | 2,000 | Sep 2026 | ≤ 42 d | 2026-03-27 |
| A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult ParticipantsNCT07604558Number of Participants Experiencing Adverse EventsNon-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: Bretisilocin | Healthy Volunteer | 26 | Sep 2026 | ≤ 42 d | 2026-06-24 |
| A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult ParticipantsNCT07649954Maximum Observed Plasma Concentration (Cmax) of NacresertibNon-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: Nacresertib, Itraconazole | Healthy Volunteer | 12 | Sep 2026 | ≤ 42 d | 2026-07-23 |
| A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsNCT02099058Number of Participants with Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Osimertinib, Nivolumab, Telisotuzumab vedotin, Telisotuzumab vedotin, Erlotinib | Advanced Solid Tumors Cancer | 237 | Aug 2026 | ≤ 12 d | 2025-08-14 |
| A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.NCT03539744Progression-Free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Pomalidomide, Dexamethasone, Venetoclax | Multiple Myeloma | 265 | Aug 2026 | ≤ 12 d | 2025-06-19 |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT04514653Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) scoreRandomized · Single-masked · Treatment | Phase 2 | Active, not recruiting | Biological: Ranibizumab · Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, ABBV-RGX-314 Dose 4 · Drug: Local Steroid, Topical Steroid | Neovascular Age-Related Macular Degeneration (nAMD) | 146 | Aug 2026 | ≤ 12 d | 2026-02-27 |
| A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabNCT06389136Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose | Atopic Dermatitis | 200 | Aug 2026 | ≤ 12 d | 2026-07-06 |
| A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsNCT07032597Percentage of Participants Achieving "Responder" Status Based on the Evaluating Investigator's (EI) Live Assessment of Mid-Face Volume Deficit Scale (MFVDS)Randomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Device: HArmonyCa Lidocaine Injectable Gel, Restylane® Perlane® Lidocaine | Mid Face Volume Deficit | 252 | Aug 2026 | ≤ 12 d | 2025-08-14 |
| A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseNCT07284381Change from Baseline in Ocular Surface Disease Index (OSDI) ScoreRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: ABBV-444, REFRESH OPTIVE UD | Dry Eye Disease | 261 | Aug 2026 | ≤ 12 d | 2026-06-17 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536Overall Response Rate (ORR) (Stage 1 and Stage 2)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Telisotuzumab vedotin | Non-small Cell Lung Cancer | 270 | Jul 2026 | — | 2025-11-05 |
| A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in SpainNCT06125795observationalChange in Participant Functioning Measured Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the EORTC Chronic Lymphocytic Leukemia 17 (EORTC-CLL17) Supplement | — | Active, not recruiting | — | Chronic Lymphocytic Leukemia | 146 | Jul 2026 | — | 2026-05-01 |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab SoravtansineNCT06682988Randomized Phase 2 Cohort: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Mirvetuximab Soravtansine | Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers | 110 | Jul 2026 | — | 2026-05-26 |
| A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral ContraceptivesNCT07414784Number of Participants with Adverse Events (AEs)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-295, Levonorgestrel/Ethinyl Estradiol | Healthy Volunteer | 20 | Jul 2026 | — | 2026-04-27 |
| A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.NCT07567781Number of Participants with Adverse Events (AEs)Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: ABBV-722, Midazolam, Metformin, Digoxin, Pitavastatin, Sitagliptin | Healthy Volunteers | 12 | Jul 2026 | — | 2026-07-20 |
| A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult ParticipantsNCT07599761Maximum Observed Plasma Concentration (Cmax) of ABBV-722Open-label · Basic science | Phase 1 | Recruiting | Drug: ABBV-722, Itraconazole | Healthy Volunteers | 12 | Jul 2026 | — | 2026-05-20 |
| A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in GreeceNCT04159779observationalOverall Response Rate (ORR) | — | Active, not recruiting | — | Chronic Lymphocytic Leukemia | 180 | 2026-06-30 | — | 2025-07-17 |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionNCT06365853Number of Participants With MIRV-related Corneal TEAEs (≥ Grade 2) in Asymptomatic ParticipantsRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops | Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive | 100 | Jun 2026 | — | 2026-06-12 |
| Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World DataNCT07419347observationalPercentage of Participants Experiencing Adverse Events | — | Recruiting | — | Hepatitis C Virus (HCV) | 2,000 | Jun 2026 | — | 2026-04-16 |
| Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06806293Change in Number of Migraine Days Occurring During the Perimenstrual Period (PMP) Averaged Across 3 Menstrual Cycles During the Double-Blind PeriodRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Atogepant, Placebo for Atogepant | Menstrual Migraine (MM) | 468 | 2026-06-29actual | — | 2026-07-30 |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)NCT04567550Part 1: Proportion of participants achieving a 2-step or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography at Week 48Randomized · Single-masked · Treatment | Phase 2 | Active, not recruiting | Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, ABBV-RGX-314 Dose 4 · Drug: Topical Steroid · Biological: Aflibercept | Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME) | 139 | 2026-06-18actual | — | 2026-08-19 |
| A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaNCT03933735Number of Participants with Dose-limiting toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: TNB-383B | Multiple Myeloma | 220 | May 2026 | — | 2026-02-06 |
| A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult ParticipantsNCT07222709Number of Participants Experiencing Adverse EventsRandomized · Triple-masked · Basic science | Phase 1 | Recruiting | Drug: ABBV-1042, Placebo | Healthy Volunteer | 48 | May 2026 | — | 2025-10-30 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsNCT03893955Dose Expansion: Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-927, ABBV-368, ABBV-181, Carboplatin, Nab-paclitaxel | Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors | 150 | Mar 2026 | — | 2025-08-12 |
| Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in ChinaNCT05144243Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: Venetoclax, Azacitidine | Acute Myeloid Leukemia (AML) | 44 | Mar 2026 | — | 2025-08-12 |
| A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in JapanNCT05286229Number of Dose-Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Etentamig | Relapsed/Refractory Multiple Myeloma | 8 | Mar 2026 | — | 2025-08-08 |
| A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological MalignanciesNCT03557619Tmax of VenetoclaxOpen-label · Basic science | Phase 1 | Recruiting | Drug: Venetoclax, ethinyl estradiol/levonorgestrel | Hematologic Malignancies | 12 | 2026-03-21 | — | 2024-08-29 |
| Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsNCT04721015Number of Participants Experiencing Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-637, Docetaxel, Osimertinib | Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC) | 81 | Feb 2026 | — | 2025-07-03 |
| Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's DiseaseNCT06937034observationalMean Base Infusion Rate | — | Recruiting | — | Parkinson's Disease | 2,000 | Dec 2025 | — | 2025-08-05 |
| Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigraineNCT06241313Percentage of Participants Achieving Pain Freedom at 2 Hours After the Double-Blind (DB) Dose for the First AttackRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Atogepant, Placebo for Atogepant | Migraine | 1,300 | 2025-07-07actual | — | 2026-06-24 |
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisNCT04468984Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Navitoclax, Ruxolitinib, Best Available Therapy (BAT) | Myelofibrosis (MF) | 330 | 2025-01-29actual | — | 2026-01-09 |
| A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 TabletsNCT05308654Overall Response Rate (ORR) per International Myeloma Working Group (IMWG) CriteriaNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ABBV-453, Dexamethasone, Daratumumab, Lenalidomide | Relapsed/Refractory Multiple Myeloma | 34 | 2024-02-07actual | — | 2025-08-14 |
| Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of CareNCT04780516observationalPercentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0 or 1 | — | Active, not recruiting | — | Psoriasis | 141 | 2024-01-02actual | — | 2025-08-13 |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNNCT03386513To assess the rate of composite CR in BPDCN patientsOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: IMGN632 | Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm | 179 | 2023-09-06actual | — | 2024-12-16 |
| A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction TherapyNCT02993523results2023-01-27Overall Survival (OS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Azacitidine, Venetoclax, Placebo | Acute Myeloid Leukemia (AML) | 443 | 2021-12-01actual | — | 2026-06-11 |
| A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisNCT03568318results2022-03-31Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Placebo, Upadacitinib, Topical corticosteroids (TCS) | Atopic Dermatitis | 1,533 | 2021-02-16actual | — | 2025-12-23 |
| A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapyNCT03675308results2022-02-24Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 3 | Active, not recruiting | Biological: Placebo, Risankizumab | Psoriatic Arthritis | 964 | 2020-10-08actual | — | 2025-08-05 |
| A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159results2019-10-07Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib | Rheumatoid Arthritis | 1,629 | 2017-10-27actual | — | 2025-08-05 |
| Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinNCT06093503PFS in the Population of Participants with no Central Nervous System (CNS) Metastases at BaselineRandomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Strategic considerations | Drug: Telisotuzumab Vedotin, Osimertinib, Cisplatin, Carboplatin, Pemetrexed | Non-Small Cell Lung Cancer | 0 | 2028-04-11 | in 601 d | 2024-06-26 |
| A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeNCT03659669observationalOverall Response Rate (ORR) | — | Suspendedsponsor's stated reason: Strategic considerations | — | Chronic Lymphocytic Leukemia (CLL) | 272 | 2027-02-28 | in 193 d | 2023-10-23 |
| A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)NCT06058728observationalPercentage of Participants with Meaningful Hair Loss | — | Withdrawnsponsor's stated reason: Company Decision | — | Uterine Fibroids (UF) | 0 | Aug 2026 | ≤ 12 d | 2025-09-17 |
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisNCT05316220Percentage of Participants Maintaining Clinical Remission Responder Status Based on the modified Mayo Score (mMS)Randomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: strategic considerations | Drug: Mesalamine, Placebo | Ulcerative Colitis (UC) | 0 | 2026-07-19 | — | 2025-08-12 |
| Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy VolunteersNCT07587008Number of Participants with Adverse Events (AEs)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Emraclidine | Healthy Volunteers | 12 | 2026-07-17actual | — | 2026-08-14 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo | Rheumatoid Arthritis | 487 | 2026-07-15actual | — | 2026-08-14 |
| ELAPR002f Injectable Gel in the Treatment of Atrophic Acne ScarsNCT05995340Percentage of Participants Achieving "Responder" Status Based on the Allergan Acne Scar Improvement Scale (ASIS)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Device: ELAPR002f Injectable Gel · Other: Saline Active Control | Atrophic Acne Scars | 157 | 2026-07-14actual | — | 2026-08-17 |
| A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial AppearanceNCT07186595Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q™ Satisfaction with Facial Appearance ScaleOpen-label · Treatment | Phase 4 | Completed | Device: JUVÉDERM VOLUX XC, JUVÉDERM VOLUMA XC, JUVÉDERM VOLBELLA XC, JUVÉDERM VOLLURE XC, SKINVIVE by JUVÉDERM, JUVÉDERM ULTRA XC, JUVÉDERM ULTRA PLUS XC | Mid Face Volume Deficit | 75 | 2026-07-08actual | — | 2026-08-10 |
| A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female ParticipantsNCT07502417Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and LevonorgestrelOpen-label · Basic science | Phase 1 | Completed | Drug: Ethinyl Estradiol + Levonorgestrel, ABBV-722 | Healthy Volunteer | 15 | 2026-07-02actual | — | 2026-07-30 |
| A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian ParticipantsNCT06673238Number of Participants with Adverse Events Reported During Safety EvaluationsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ABBV-722, Placebo | Healthy Volunteer | 95 | 2026-06-25actual | — | 2026-07-27 |
| Long-term Safety and Efficacy Extension Trial of Bimatoprost SRNCT03891446Duration of effect of Bimatoprost SRNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Bimatoprost SR · Other: Standard of Care | Open-Angle Glaucoma, Ocular Hypertension | 455 | 2026-06-19actual | — | 2026-07-15 |
| A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy VolunteersNCT07413133Number of Participants with Adverse Events (AEs)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-8736, ABBV-8736 | Healthy Volunteer | 40 | 2026-06-19actual | — | 2026-07-20 |
| Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic LeukemiaNCT03415035observationalBest Response of Venetoclax in Participants with Chronic Lymphocytic Leukemia (CLL) up to 12 Months | — | Completed | — | Cancer - Chronic Lymphocytic Leukemia | 269 | 2026-06-17actual | — | 2026-07-23 |
| A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese ParticipantsNCT07600762Maximum Observed Plasma Concentration (Cmax) of NacresertibRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: Nacresertib, Placebo for Nacresertib | Healthy Volunteer | 12 | 2026-06-17actual | — | 2026-07-20 |
| An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic ArthritisNCT05616871observationalPercentage of Participants Achieving Disease Activity in Psoriatic Arthritis (DAPSA): score <=14 | — | Completed | — | Psoriatic Arthritis | 464 | 2026-06-11actual | — | 2026-07-27 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult ParticipantsNCT07136103Maximum Plasma Concentration (Cmax) of ABBV-277Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: ABBV-277, Placebo | Healthy Volunteers | 32 | 2026-06-11actual | — | 2026-07-08 |
| A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult ParticipantsNCT07425899Maximum observed plasma concentration at steady state (Cmax,ss) of ABBV-722Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-722, Upadacitinib | Healthy Volunteer | 16 | 2026-06-05actual | — | 2026-08-04 |
| A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite SystemNCT07122583Number of Participants with Device and/or Procedure-Related Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 4 | Completed | Device: CoolSculpting Elite System | Non-Surgical Fat Reduction | 102 | 2026-06-03actual | — | 2026-07-02 |
| Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In CanadaNCT06692881observationalPercentage of Participants Achieving Functional Disability Scale (FDS) Score of =0, no disability, able to function normally 4 hours post-dose | — | Completed | — | Migraine | 178 | 2026-06-01actual | — | 2026-06-29 |
| An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in ChinaNCT06421740observationalNumber of participants with a dose change | — | Completed | — | Atopic Dermatitis | 1,000 | 2026-05-25actual | — | 2026-08-14 |
| A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult ParticipantsNCT06849791Maximum Plasma Concentration (Cmax) of ABBV-932Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-932, ABBV-932 | Healthy Volunteer | 9 | 2026-05-08actual | — | 2026-06-04 |
| An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung CancerNCT04189614Objective Response Rate (ORR)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Cofetuzumab Pelidotin | Cancer, Non-small Cell Lung Cancer (NSCLC) | 65 | 2026-05-07actual | — | 2026-06-04 |
| Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic DermatitisNCT05959083observationalPercentage of Participants With Incidence of Serious Infections | — | Completed | — | Atopic Dermatitis (AD) | 200 | 2026-05-07actual | — | 2026-06-04 |
| A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult ParticipantsNCT07566130Maximum Observed Plasma Concentration (Cmax) of nacresertibRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: nacresertib, Placebo | Healthy Volunteers | 93 | 2026-05-07actual | — | 2026-06-04 |
| Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's DiseaseNCT04750226Percentage of Participants with Adverse Event (AEs)Open-label · Treatment | Phase 3 | Completed | Drug: ABBV-951 | Parkinson's Disease (PD) | 118 | 2026-04-27actual | — | 2026-06-01 |
| Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's DiseaseNCT04379050Percentage of Participants With Adverse Events (AE)Open-label · Treatment | Phase 3 | Completed | Drug: ABBV-951 | Parkinson's Disease (PD) | 130 | 2026-04-17actual | — | 2026-05-13 |
| A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)NCT02942290AUCt for AzacitidineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Azacitidine, Venetoclax | Myelodysplastic Syndromes (MDS) | 134 | 2026-04-15actual | — | 2026-08-12 |
| A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult ParticipantsNCT06774313Number of Participants with Adverse Events (AEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: ABBV-142, ABBV-142, Placebo, Placebo | Healthy Volunteer | 73 | 2026-04-08actual | — | 2026-05-06 |
| A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult ParticipantsNCT06794866Percentage of Participants who Achieve 'None' or 'Mild' on Facial Wrinkle Scale with Asian Photonumeric Guide (FWS-A) According to the Investigator Assessment of Forehead Lines (FHL) Severity at Maximum ContractionRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: OnabotulinumtoxinA, Placebo | Forehead Lines | 150 | 2026-04-03actual | — | 2026-05-05 |
| A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy VolunteersNCT07141199Number of Participants with Adverse Events (AEs)Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: ABBV-8736, Placebo | Healthy Volunteer | 24 | 2026-03-23actual | — | 2026-04-28 |
| A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult ParticipantsNCT07361367Maximum Observed Plasma Concentration (Cmax) of ABBV-722Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-722 | Healthy Volunteers | 11 | 2026-03-23actual | — | 2026-04-24 |
| A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica ProductsNCT06783621Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Satisfaction with Facial Appearance Scale at the Final VisitNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: OnabotulinumtoxinA, KYBELLA · Device: JUVÉDERM, CoolSculpting Elite System · Other: SkinMedica Products | Facial Contouring | 130 | 2026-03-20actual | — | 2026-05-22 |
| A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)NCT06333860Period A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90)Randomized · Single-masked · Treatment | Phase 4 | Completed | Drug: Risankizumab, Deucravacitinib | Moderate Plaque Psoriasis | 393 | 2026-03-19actual | — | 2026-04-15 |
| A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel DiseaseNCT06346288To determine the concentration of risankizumab in breastmilkOpen-label · Other | Phase 4 | Completed | Procedure: Breast Milk Sampling · Drug: Risankizumab | Inflammatory Bowel Disease | 10 | 2026-02-05actual | — | 2026-04-20 |
| A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin QualityNCT06547125Percentage of Participants Achieving "Responder" Status for Evaluating Investigator's (EI) Live Assessment of Global Aesthetic Improvement in Skin Quality on the Treatment Area Using the Global Aesthetic Improvement Scale (GAIS)Randomized · Single-masked · Treatment | Phase 2/3 | Completed | Device: JUVÉDERM® VOLITE™ · Other: Control | Skin Quality Deficit | 135 | 2026-02-05actual | — | 2026-02-18 |
| Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle GlaucomaNCT05411198Percentage of Participants Achieving Effectiveness of XEN45Open-label · Treatment | Phase 3 | Completed | Device: XEN45 (Glaucoma Gel Stent) | Open-Angle Glaucoma | 74 | 2026-02-04actual | — | 2026-02-27 |
| An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult ParticipantsNCT05827887observationalUbrogepant (UBRO) Only: Percentage of Participants with Responder Status of "Extremely Satisfied" or "Satisfied" on a Single Item 7-Point Scale | — | Completed | — | Migraine | 226 | 2026-01-28actual | — | 2026-04-03 |
| Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)NCT04295538Upper Extremity Motor Score (UEMS)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Elezanumab, Placebo | Spinal Cord Injury (SCI) | 60 | 2026-01-26actual | — | 2026-02-11 |
| Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I DisorderNCT06256367observationalChange From Baseline on Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | — | Completed | — | Bipolar I Disorder | 120 | 2026-01-23actual | — | 2026-02-24 |
| A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult ParticipantsNCT07007091Maximum Observed Plasma Concentration (Cmax) of RisankizumabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Risankizumab, Risankizumab | Healthy Volunteers | 260 | 2026-01-15actual | — | 2026-01-27 |
| A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult ParticipantsNCT06698926Number of Participants with Adverse Events (AEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: ABBV-CLS-616, Placebo, Itraconazole | Healthy Volunteer | 110 | 2026-01-09actual | — | 2026-01-15 |
| A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295NCT06144684Safety - Adverse Events (AE) incidenceRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: GUB014295, GUB014295-PLACEBO | Healthy Volunteers, Overweight | 76 | 2026-01-05actual | — | 2026-01-15 |
| A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic DermatitisNCT06390722Percentage of participants achieving an improvement (reduction) in Worst Pruritus Numeric Rating Scale ≥ 4 from BaselineRandomized · Triple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: strategic decision | Drug: Upadacitinib, Placebo for Upadacitinib | Atopic Dermatitis, Sleep Disturbance | 0 | 2026-01-05 | — | 2024-09-19 |
| A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic ArthritisNCT04541810observationalPercentage of Participants With Adverse Events | — | Completed | — | Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | 2,369 | 2025-12-31actual | — | 2026-02-12 |
| Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World JapanNCT05609643observationalIncidence Percentage of Serious Infection as Adverse Drug Reactions ( ADR) | — | Completed | — | Ankylosing Spondylitis | 69 | 2025-12-11actual | — | 2026-02-17 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in JapanNCT05791526observationalIncidence Percentage of Serious Infection Reported as Adverse Drug Reaction (ADR) | — | Completed | — | Ulcerative Colitis | 308 | 2025-12-09actual | — | 2025-12-31 |
| Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's DiseaseNCT06459297observationalPercentage of participants who reported Serious Adverse Event | — | Completed | — | Ulcerative Colitis, Crohn's Disease | 105 | 2025-12-09actual | — | 2026-01-08 |
| A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male ParticipantsNCT07219017Number of Participants with Adverse Events (AEs)Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-1354 | Healthy Volunteer | 8 | 2025-12-09actual | — | 2026-01-05 |
| Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese ParticipantsNCT07024797Maximum Plasma Concentration (Cmax) of ABBV-932Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: ABBV-932, Placebo for ABBV-932 | Healthy Volunteer | 20 | 2025-12-08actual | — | 2025-12-31 |
| A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult ParticipantsNCT05818709Percentage of Participants Achieving "Responder" Status Based on the Evaluating Investigator's (EI) live assessment of Mid-Face Volume Deficit Scale (MFVDS)Randomized · Single-masked · Treatment | Phase 3 | Completed | Device: HAC 22L | Facial Volume Deficit | 61 | 2025-12-05actual | — | 2025-12-26 |
| Open-label Trial in Parkinson's Disease (PD)NCT04760769Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Completed | Drug: Tavapadon | Parkinson Disease | 992 | 2025-12-01actual | — | 2025-12-23 |
| A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle ProminenceNCT06387394Composite Achievement of MMP Severity Improvement and at Least a 2-Grade Improvement from Baseline by Both Investigator-Rated MMPS and Participant-Rated MMPS-PRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: BOTOX, Placebo | Masseter Muscle Prominence | 202 | 2025-11-25actual | — | 2025-12-11 |
| A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult ParticipantsNCT06946524Maximum Observed Plasma Concentration (Cmax) of RisankizumabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Risankizumab | Healthy Volunteers | 59 | 2025-11-25actual | — | 2025-12-26 |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax TabletsNCT05215639observationalPercentage of Participants Achieving Overall Survival (OS) | — | Completed | — | Acute Myeloid Leukemia | 120 | 2025-11-24actual | — | 2025-12-10 |
| A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsNCT06068855Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale (MMPS) as assessed by the InvestigatorRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: BOTOX, Placebo | Masseter Muscle Prominence | 249 | 2025-11-20actual | — | 2025-12-10 |
| A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's DiseaseNCT05291234Number of Participants Experiencing Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ABBV-916, Placebo | Alzheimer's Disease (AD) | 106 | 2025-11-19actual | — | 2025-12-10 |
| Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in ChinaNCT07058051observationalTotal Vitiligo Area Scoring Index (T-VASI) | — | Completed | — | Non-Segmental Vitiligo | 100 | 2025-11-13actual | — | 2025-11-19 |
| Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderNCT06605599Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ABBV-932, Placebo for ABBV-932 | Bipolar I Disorder, Bipolar II Disorder | 161 | 2025-11-12actual | — | 2026-01-12 |
| A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsNCT06399718Composite Achievement of MMP Severity Improvement and at Least a 2-Grade Improvement from Baseline by Both Investigator-Rated MMPS and Participant-Rated MMPS-PRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: BOTOX, Placebo | Masseter Muscle Prominence | 207 | 2025-11-10actual | — | 2026-08-12 |
| A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult ParticipantsNCT06937619Maximum Observed Plasma Concentration (Cmax) of RisankizumabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Risankizumab | Healthy Volunteer | 263 | 2025-11-10actual | — | 2025-11-17 |
| A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)NCT06834789Number of Participants with Adverse Events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AGN-151586, OnabotulinumtoxinA, Placebo | Glabellar Lines | 132 | 2025-11-03actual | — | 2025-11-17 |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsNCT06158958Percentage of Participants With Adverse Events (AE)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-303, Budigalimab | Solid Tumors | 27 | 2025-10-22actual | — | 2025-10-27 |
| A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineNCT04686136Percentage of Participants with at Least 1 Treatment Emergent Adverse EventOpen-label · Treatment | Phase 3 | Completed | Drug: Atogepant 60 mg | Episodic Migraine, Chronic Migraine | 596 | 2025-10-20actual | — | 2025-12-18 |
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)NCT04826523observationalPercentage of Participants Who Reported Serious Adverse Event/Drug Reaction | — | Completed | — | Acute Myeloid Leukemia (AML) | 150 | 2025-10-20actual | — | 2025-11-26 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT05105841Complete Remission (CR) with an Incomplete Marrow Recovery (CRi) Rate, as Assessed by an Independent Review Committee (IRC) per Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) for Venetoclax + Obinutuzumab (V+G)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Venetoclax, Ibrutinib, Obinutuzumab | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 20 | 2025-10-09actual | — | 2025-10-15 |
| A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female ParticipantsNCT06742086Number of Participants with Adverse Events (AE)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Venetoclax | Healthy Volunteer | 72 | 2025-10-08actual | — | 2025-10-15 |
| Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderNCT04578756Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment PeriodNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Cariprazine Flexible Dose, Cariprazine Flexible Dose | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 310 | 2025-10-06actual | — | 2025-10-27 |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)NCT04161885results2026-06-04Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Venetoclax, Azacitidine · Other: Best Supportive Care (BSC) | Acute Myeloid Leukemia (AML), Cancer | 465 | 2025-09-23actual | — | 2026-06-04 |
| A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive DisorderNCT06618118Number of Participants Experiencing Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: Fosigotifator, Placebo | Major Depressive Disorder (MDD) | 20 | 2025-09-23actual | — | 2025-09-30 |
| A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382NCT06032546Percentage of Participants with Viral Control Without Antiretroviral Therapy (ART) RestartRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Company Decision | Drug: Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382, Budigalimab | Human Immuno-deficiency Virus (HIV) Disease | 163 | 2025-09-22actual | — | 2025-10-29 |
| A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)NCT05029895observationalPercentage of Participants with Serious Infection | — | Completed | — | Atopic Dermatitis | 167 | 2025-09-17actual | — | 2026-02-27 |
| A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult ParticipantsNCT06887010Number of Participants Experiencing Adverse EventsRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-101 | Healthy Volunteer | 17 | 2025-09-16actual | — | 2025-10-02 |
| A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid TumorsNCT03595059MTD and/or RPTD of ABBV-155Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-155, Paclitaxel, Docetaxel | Advanced Solid Tumors | 168 | 2025-09-12actual | — | 2025-12-10 |
| A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088NCT06579300Part 1, 2 and 3: Maximum Plasma Concentration (Cmax) of ABBV-1088Randomized · Triple-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ) | Healthy Volunteer | 72 | 2025-09-03actual | — | 2025-10-30 |
| Observational Study of Patients With Moderate to Severe Chronic Plaque PsoriasisNCT03982394observationalPercentage of participants who achieved Psoriasis Area and Severity Index (PASI) 90 | — | Completed | — | Chronic Plaque Psoriasis | 2,759 | 2025-09-02actual | — | 2025-11-17 |
| A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional ConstipationNCT05652205results2026-05-14Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo for Linaclotide, Linaclotide | Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | 123 | 2025-09-02actual | — | 2026-05-14 |
| First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic TumorsNCT04417465Maximum Observed Plasma/Serum Concentration (Cmax) Of ABBV-CLS-579Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI | Advanced Solid Tumors Cancer | 101 | 2025-08-21actual | — | 2025-09-25 |
| A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical PracticeNCT04178317observationalNumber of Participants With Adverse Events | — | Completed | — | Cancer, Chronic Lymphocytic Leukemia (CLL) | 14 | 2025-08-18actual | — | 2025-12-04 |
| Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ TabletsNCT04340115observationalNumber (Percentage) Of Participants Who Reported Of Serious Infection | — | Completed | — | Rheumatoid Arthritis (RA) | 4,211 | 2025-08-15actual | — | 2026-06-03 |
| Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionNCT03850782Retreatment or rescue administered for IOPNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Bimatoprost (SR) | Open-Angle Glaucoma, Ocular Hypertension | 515 | 2025-08-08actual | — | 2025-08-19 |
| Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in TaiwanNCT04818385observationalThe Percentage of Participants who Achieved Psoriasis Area and Severity Index (PASI) 90 | — | Completed | — | Psoriasis | 240 | 2025-08-01actual | — | 2025-09-17 |
| A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult ParticipantsNCT06137287Percentage of Participants who Achieve >= 2-Grade Improvement on Investigator-Rated Masseter Muscle Prominence Scale (MMPS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: BOTOX, Placebo for BOTOX | Masseter Muscle Prominence | 259 | 2025-07-31actual | — | 2026-07-06 |
| A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female ParticipantsNCT06070948Maximum Observed Plasma Concentration (Cmax) of VenetoclaxRandomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Strategic considerations | Drug: Venetoclax | Healthy Volunteers | 0 | 2025-07-28 | — | 2024-06-21 |
| Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's DiseaseNCT02906488observationalChange in "Off" Periods From Start of Treatment to Week 104 | — | Completed | — | Parkinson's Disease | 839 | 2025-07-24actual | — | 2025-08-24 |
| A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseNCT02782663results2026-08-13Percentage of Participants Achieving Endoscopic Remission at Month 12Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ABT-494 | Crohn's Disease (CD) | 107 | 2025-07-18actual | — | 2026-08-13 |
| A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral SclerosisNCT04948645Safety and TolerabilityRandomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: Fosigotifator, Placebo | ALS, Amyotrophic Lateral Sclerosis | 31 | 2025-07-15actual | — | 2025-08-01 |
| A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and CapsulesNCT04464187observationalRate of major congenital malformations | — | Terminatedsponsor's stated reason: Company Decision | — | Endometriosis, Uterine Fibrioids | 173 | 2025-07-11actual | — | 2025-09-15 |
| A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaNCT05443724Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 2 | Completed | Drug: CVL-231 30 mg | Schizophrenia | 700 | 2025-06-25actual | — | 2025-07-28 |
| A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult ParticipantsNCT06895356Number of Participants Experiencing Adverse EventsRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Tavapadon | Healthy Volunteer | 83 | 2025-06-16actual | — | 2025-06-26 |
| Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic ArthritisNCT04433442observationalNumber of Participants who Reported Adverse Events | — | Completed | — | Psoriasis, Psoriatic Arthritis | 2,324 | 2025-06-13actual | — | 2026-04-27 |
| A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)NCT04064827results2026-06-15Percentage of Participants Who Achieve Positive Response During Dosing Period 1Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Company Decision | Drug: Paricalcitol | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | 2 | 2025-06-09actual | — | 2026-06-15 |
| A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With LinaclotideNCT05760313results2026-01-06Change From Baseline in Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Linaclotide, Placebo | Functional Constipation | 19 | 2025-06-09actual | — | 2026-01-06 |
| Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-CNCT04166058results2026-01-06Number of Participants With Treatment-Emergent Adverse Events (TEAEs).Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | Irritable Bowel Syndrome With Constipation, Functional Constipation | 381 | 2025-06-05actual | — | 2026-01-06 |
| Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative ColitisNCT05785715results2026-06-15Change From Baseline in Modified Mayo Score (MMS) at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision\_Not Safety Related | Drug: NX-13 250mg, NX-13 750mg, NX-13 Placebo | Ulcerative Colitis | 81 | 2025-05-30actual | — | 2026-06-15 |
| Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral PalsyNCT06150729observationalAbsolute Total Dose | — | Completed | — | Spasticity | 107 | 2025-05-30actual | — | 2026-08-06 |
| Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy VolunteersNCT06300580Change in Dopamine Receptor Occupancy in Brain Measured by Positron Emission Tomography (PET)Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-932 | Healthy Volunteers | 11 | 2025-05-26actual | — | 2025-06-05 |
| A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese VolunteersNCT06632938Number of Participants with Adverse Events (AEs)Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: ABBV-382, ABBV-382, Placebo for ABBV-382, Placebo for ABBV-382 | Healthy Volunteer | 24 | 2025-05-15actual | — | 2025-05-30 |
| Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT04570631Recommended Phase 2 Dose (RP2D) of Eftozanermin Alfa in Combination With Bortezomib and Dexamethasone (Safety Lead-In Arm)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Eftozanermin alfa, Bortezomib, Dexamethasone | Multiple Myeloma | 4 | 2025-05-05actual | — | 2025-05-16 |
| Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic MigraineNCT05216263results2026-06-16Number of Participants With Adverse Events (AEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Atogepant | Chronic Migraine | 75 | 2025-05-02actual | — | 2026-06-16 |
| Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With MigraineNCT05748483results2026-07-02Percentage of Participants Who Discontinued Treatment Due to Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Atogepant, Placebo for Atogepant, Topiramate, Placebo for Topiramate | Migraine | 545 | 2025-04-28actual | — | 2026-07-02 |
| A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation TechniqueNCT05606757Percentage of participants with achievement of primary fascial closure (PFC) without the use of component separation techniques (CST) in open ventral hernia surgical repairRandomized · Triple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Strategic considerations | Drug: BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B, BOTOX Dose C | Ventral Hernia, Abdominal Hernia | 0 | 2025-04-22 | — | 2024-05-16 |
| A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy ParticipantsNCT06406348Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ALIA-1758 · Other: Placebo | Alzheimer Disease | 53 | 2025-04-22actual | — | 2025-07-17 |
| A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult ParticipantsNCT06571266Number of Participants with Adverse Events (AEs)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Risankizumab | Healthy Volunteers | 231 | 2025-04-16actual | — | 2025-05-16 |
| A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's DiseaseNCT05644977Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Emraclidine, Placebo | Healthy Participants, Alzheimer's Disease Dementia | 17 | 2025-04-14actual | — | 2025-05-02 |
| Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative ColitisNCT02632175results2025-10-16Number of Participants With Adverse Events (AEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Adalimumab | Ulcerative Colitis | 59 | 2025-04-08actual | — | 2025-10-16 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic DisorderNCT05941442results2026-05-07Percentage of Participants Free of Panic Attacks as Assessed by Participant Daily eDiary During the Last Two Weeks of the Maintenance Treatment PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor terminated due to significant enrollment and study design challenges | Drug: Darigabat, Placebo | Panic Disorder | 80 | 2025-03-31actual | — | 2026-05-07 |
| A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving UpadacitinibNCT04846244observationalPercentage of Participants with a Total Spinal Pain Score < 4 and >= 2 Unit (0 - 10) Improvement | — | Completed | — | Axial Spondylarthritis (axSpA) | 708 | 2025-03-24actual | — | 2026-03-25 |
| An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)NCT05959070observationalValidity of the Cumulative Life Course Impairment Instrument (DermCLCI-p) | — | Completed | — | Psoriasis | 154 | 2025-03-21actual | — | 2026-03-25 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)NCT06024239Maximum Observed Plasma Concentration (Cmax)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ABBV-932, Placebo for ABBV-932 | Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD) | 72 | 2025-03-04actual | — | 2025-03-17 |
| Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineNCT05861427results2026-06-11Change From Baseline in Mean Monthly Migraine DaysRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Atogepant, Placebo for Atogepant | Migraine | 524 | 2025-03-01actual | — | 2026-06-11 |
| A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar LinesNCT06308198Percentage of Participants with a >= 2-Grade Improvement from Baseline on the Facial Wrinkle Scale with Asian (FWS-A) Guide According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum FrownRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: AGN-151586, Placebo | Glabellar Lines | 161 | 2025-02-26actual | — | 2026-06-26 |
| Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NCT06068868Number of Participants with Adverse Events (AE)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-787 | Acute Myeloid Leukemia | 36 | 2025-02-25actual | — | 2025-03-06 |
| A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult ParticipantsNCT06151535Percentage of Participants Achieving Responder Status Based on Evaluating Investigator's Live Assessment of Each Cheek Separately Using Allergan Cheek Smoothness Scale (ACSS)Randomized · Open-label · Treatment | Phase 2 | Completed | Device: ELAPR002f Injectable Gel | Skin Quality Deficit | 30 | 2025-02-24actual | — | 2025-03-05 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of EmraclidineNCT05935033Maximum Observed Plasma Concentration (Cmax) of EmraclidineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Emraclidine | Hepatic Impairment | 38 | 2025-02-21actual | — | 2025-04-04 |
| A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related ApathyNCT04958031results2026-03-11Number of Participants With Adverse EventsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision - Not Safety Related | Drug: CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo | Apathy in Dementia | 41 | 2025-02-12actual | — | 2026-03-11 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.NCT06414798Maximum Plasma Concentration (Cmax) of ABBV-1088Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: Drug: ABBV-1088, Drug: Placebo for ABBV-1088 | Healthy Volunteers | 60 | 2025-02-08actual | — | 2025-02-19 |
| Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersNCT00788684Extension Study: Continued assessment of the safety profile of ABT-263 when administered in combination with rituximabOpen-label · Treatment | Phase 1 | Completed | Drug: rituximab, ABT-263 | CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma | 29 | 2025-02-07actual | — | 2025-02-20 |
| A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy ParticipantsNCT06487572Number of Participants Experiencing Adverse EventsRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Risankizumab, Risankizumab | Healthy Volunteers | 60 | 2025-02-07actual | — | 2025-02-18 |
| Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential TremorNCT05216250Change From Baseline in Tremor Disability Scale-Revised (TREDS-R) Total Score Across 7 Unilateral ItemsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: BOTOX · Drug: Placebo for BOTOX | Upper Limb Essential Tremor (UL ET) | 174 | 2025-02-03actual | — | 2026-01-20 |
| A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial FoldsNCT06018987Percentage of Participants Achieving Responder Status Based on Evaluating Investigator's (EI's) Live Assessment of Nasolabial Folds (NLF) Severity using the Nasolabial Fold Severity Scale (NLFSS)Randomized · Single-masked · Treatment | Phase 2/3 | Completed | Other: No-Treatment Control · Device: HAC 20L | Nasolabial Folds | 61 | 2025-02-03actual | — | 2025-02-11 |
| A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult VolunteersNCT06078202Maximum Observed Plasma Concentration (Cmax) of ABBV-903Randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Strategic considerations | Drug: ABBV-903 | Healthy Volunteers | 0 | 2025-01-31 | — | 2024-09-20 |
| Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp PsoriasisNCT05969223results2026-02-24Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Risankizumab, Placebo for Risankizumab | Genital Psoriasis, Scalp Psoriasis | 214 | 2025-01-22actual | — | 2026-02-24 |
| A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese ParticipantsNCT06722417Maximum Observed Plasma Concentration (Cmax) of IcalcaprantNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Icalcaprant | Healthy Volunteer | 16 | 2025-01-17actual | — | 2025-01-28 |
| A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult ParticipantsNCT06722430Maximum Observed Plasma Concentration (Cmax) of IcalcaprantOpen-label · Basic science | Phase 1 | Completed | Drug: Icalcaprant, Itraconazole (ITZ) | Healthy Volunteer | 12 | 2025-01-13actual | — | 2025-01-28 |
| A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung CancerNCT06068842observationalPresence of Mesenchymal Epithelial Transition (MET) protein overexpression (OE) | — | Completed | — | Non Small Cell Lung Cancer | 579 | 2024-12-31actual | — | 2025-01-29 |
| A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in JapanNCT06362044observationalPercentage of Participants with Undetectable Minimal Residual Disease (uMRD) | — | Completed | — | Chronic Lymphocytic Leukemia | 89 | 2024-12-31actual | — | 2025-11-25 |
| A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian ParticipantsNCT06148181Maximum Observed Plasma Concentration (Cmax) of ABBV-141Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: ABBV-141, Placebo for ABBV-141, ABBV-141, Placebo for ABBV-141 | Healthy Volunteers | 41 | 2024-12-30actual | — | 2025-01-23 |
| A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)NCT05394805observationalNumber of Participants with Serious Adverse Events (SAEs) | — | Completed | — | Crohn's Disease | 156 | 2024-12-26actual | — | 2025-11-17 |
| Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative ColitisNCT05570006results2025-12-23Percentage of Participants Achieving Endoscopic ImprovementOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ABBV-668 | Ulcerative Colitis | 30 | 2024-12-23actual | — | 2025-12-23 |
| A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal FunctionNCT05940402Maximum Observed Plasma Concentration (Cmax) of EmraclidineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Emraclidine | Renal Impairment | 58 | 2024-12-19actual | — | 2025-04-04 |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersNCT05041257results2026-01-09Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1])Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Mirvetuximab soravtansine | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 79 | 2024-12-12actual | — | 2026-01-09 |
| A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese ParticipantsNCT05741034Percentage of Participants Achieving "Responder" status based on Evaluating Investigator's (EI) live assessment of transverse neck lines using the Allergan Transverse Neck Lines Scale (ATNLS)Randomized · Single-masked · Treatment | Phase 3 | Completed | Device: JUVÉDERM® VOLITE™ · Other: Control | Neck Lines | 159 | 2024-12-09actual | — | 2025-12-08 |
| An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresNCT04686786results2025-12-11Number of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Closed early after CVL-865-SZ-001 (NCT04244175) did not meet its primary objective | Drug: CVL-865 | Seizures | 105 | 2024-12-05actual | — | 2025-12-11 |
| A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)NCT04750213observationalIncidence Percentage of all the Infection Reported as Adverse Drug Reaction (ADR) | — | Completed | — | Pyoderma Gangrenosum | 60 | 2024-11-11actual | — | 2025-07-17 |
| Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic MigraineNCT05028569results2025-12-09Change From Baseline in the Frequency of Monthly Migraine Days Across Months 5 and 6Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated early due to lack of efficacy from the primary analysis results. | Drug: BOTOX, Placebo | Episodic Migraine | 775 | 2024-11-06actual | — | 2025-12-09 |
| A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral UpadacitinibNCT05451316observationalPercentage of participants achieving Worst Pruritus Numerical Rating Scale (WP-NRS) reduction ≥ 4. | — | Completed | — | Atopic Dermatitis | 1 | 2024-11-02actual | — | 2026-02-27 |
| A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart ReviewNCT06503536observationalNumber of participants who achieve a composite endpoint post-index score of Eczema Area and Severity Index (EASI) < =7 | — | Completed | — | Atopic Dermatitis (AD) | 150 | 2024-10-31actual | — | 2024-11-18 |
| A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT05513703results2025-10-24Objective Response Rate (ORR) as Assessed by an Independent Central Review (ICR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Strategic considerations | Biological: Telisotuzumab Vedotin | Non Small Cell Lung Cancer | 9 | 2024-10-28actual | — | 2025-10-24 |
| Effect of Long-term Psoriasis on Patients' Life - CORONATENCT05555953observationalCORONATE Questionnaire Score | — | Completed | — | Psoriasis | 543 | 2024-10-17actual | — | 2024-10-26 |
| An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)NCT06443775observationalChange from Baseline in Ocular Surface Disease Index (OSDI) Score | — | Completed | Drug: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) | Dry Eye | 47 | 2024-10-14actual | — | 2025-07-14 |
| A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled SyringeNCT06402513Maximum Observed Plasma Concentration (Cmax)Open-label · Basic science | Phase 1 | Completed | Drug: Ravagalimab | Healthy Volunteers | 12 | 2024-10-08actual | — | 2024-10-21 |
| Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASDNCT05439616Change from Baseline in Aberrant Behavior Checklist, 2nd edition - Community Version - Irritability (ABC-I) Subscale ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Cariprazine, Placebo | Autism Spectrum Disorder | 161 | 2024-10-04actual | — | 2025-04-04 |
| Flexible-Dose Trial in Early Parkinson's Disease (PD)NCT04223193results2025-11-21Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tavapadon, Placebo | Parkinson Disease | 304 | 2024-10-01actual | — | 2025-11-21 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaNCT05368558results2025-10-20Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Cariprazine, Placebo | Schizophrenia | 34 | 2024-09-20actual | — | 2025-10-20 |
| A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult ParticipantsNCT06477926Maximum Plasma Concentration (Cmax) of ABBV-668Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-668 IR, ABBV-668 ER | Healthy Volunteers | 25 | 2024-09-20actual | — | 2024-10-08 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)NCT04903626results2025-04-06Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) PopulationOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Glecaprevir/Pibrentasvir (GLE/PIB) | Hepatitis C Virus (HCV) | 286 | 2024-09-17actual | — | 2025-04-06 |
| A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult ParticipantsNCT06174688Percentage of Participants who Achieved 'None' or 'Mild' on Facial Wrinkle Scale with Asian Photonumeric Guide (FWS-A) According to the Investigator Assessment of Forehead Lines (FHL) SeverityRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: BOTOX, Placebo | Forehead Lines | 140 | 2024-09-13actual | — | 2025-08-28 |
| A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult ParticipantsNCT05316233Percentage of Participants Achieving "Responder" status based on Evaluating Investigator's (EI) live assessment of transverse neck lines using the Allergan Transverse Neck Lines Scale (ATNLS)Randomized · Single-masked · Treatment | Phase 3 | Completed | Device: VOLITE XC, VOLITE XC | Neck Lines | 159 | 2024-09-12actual | — | 2025-04-29 |
| An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)NCT05411211observationalChange from Baseline in Physician's Global Assessment (PhGA) of Participant's Disease Activity by Visual Analog Scale (VAS) | — | Completed | — | Polyarticular Juvenile Idiopathic Arthritis | 20 | 2024-09-08actual | — | 2025-03-24 |
| A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the MouthNCT05454033The percentage of participants who achieved at least 1-point improvement from baseline on the Perioral Lines Severity Scale (POLSS)Randomized · Single-masked · Treatment | Phase 3 | Completed | Device: JUVÉDERM® VOLITE™ · Other: Control | Perioral Lines | 198 | 2024-09-03actual | — | 2025-12-02 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic DermatitisNCT03646604Maximum Plasma Concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Upadacitinib (ABT-494) | Atopic Dermatitis | 35 | 2024-08-29actual | — | 2025-02-10 |
| A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227690results2025-09-17Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, Emraclidine 10 mg, Emraclidine 30 mg | Schizophrenia | 385 | 2024-08-23actual | — | 2025-09-17 |
| Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World SettingNCT05956483observationalPositive Predictive Value (PPV) of Rapid Mood Screener (RMS) | — | Completed | — | Bipolar I Disorder | 423 | 2024-08-16actual | — | 2024-08-20 |
| A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227703results2025-10-28Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Emraclidine 15 mg, Emraclidine 30 mg, Placebo | Schizophrenia | 391 | 2024-08-15actual | — | 2025-10-28 |
| An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing DupilumabNCT05394792observationalPercentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 | — | Completed | — | Atopic Dermatitis | 111 | 2024-08-15actual | — | 2025-08-19 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's DiseaseNCT05771428results2025-10-15Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ABBV-552, Placebo for ABBV-552 | Alzheimer's Disease (AD) | 263 | 2024-08-06actual | — | 2025-10-15 |
| An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult ParticipantsNCT05653986observationalPercentage of Participants Achieving Meaningful Pain Relief | — | Completed | — | Migraine | 391 | 2024-08-05actual | — | 2026-06-03 |
| A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C VirusNCT04214028observationalNumber of Participants with Adverse Drug Reactions (ADRs) | — | Completed | — | Hepatitis C Virus (HCV) | 50 | 2024-08-01actual | — | 2025-07-20 |
| A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid ArthritisNCT04574492observationalPercentage of Participants Who Achieve Clinical Remission | — | Completed | — | Rheumatoid Arthritis (RA) | 413 | 2024-07-30actual | — | 2025-09-03 |
| A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial LinesNCT06218251results2025-08-06Percentage of Participants With Responder Status of 'Mostly Satisfied' or 'Very Satisfied' on the Facial Line Satisfaction Questionnaire (FLSQ) Follow Up Item 4 (Satisfaction With the Natural Look)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: BOTOX | Upper Facial Lines | 100 | 2024-07-25actual | — | 2025-11-24 |
| An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)NCT06439394observationalAcute Phase: Change from Baseline in Current Symptom Scores | — | Completed | Drug: Optive MEGA-3 (OM3) | Dry Eye | 52 | 2024-07-18actual | — | 2025-08-19 |
| A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic DermatitisNCT05507580results2025-07-29Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Upadacitinib | Atopic Dermatitis | 461 | 2024-07-11actual | — | 2025-07-29 |
| Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)NCT05141006Change in Average Daily Worst Bladder PainRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: BOTOX, Placebo for BOTOX | Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | 83 | 2024-07-05actual | — | 2025-05-06 |
| Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenNCT03271489results2025-07-22Number of Participants With Adverse Events (AEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Elagolix, Estradiol /norethindrone acetate (E2/NETA) · Other: E2/NETA Placebo, Elagolix Placebo | Heavy Menstrual Bleeding, Uterine Fibroids | 478 | 2024-06-28actual | — | 2025-07-22 |
| Fixed-Dose Trial in Early Parkinson's Disease (PD)NCT04201093results2025-07-28Change From Baseline in the MDS-UPDRS Parts II and III Combined ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tavapadon, Placebo, Tavapadon | Parkinson Disease | 529 | 2024-06-28actual | — | 2025-07-28 |
| A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic MigraineNCT04437433results2025-07-22Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Atogepant 60 mg | Chronic Migraine, Episodic Migraine | 186 | 2024-06-11actual | — | 2025-07-22 |
| A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-UveitisNCT05414201Percentage of participants that achieve quiescence in both eyesOpen-label · Treatment | Phase 4 | Completed | Drug: Adalimumab | Non-infectious Intermediate Posterior- or Pan-uveitis | 87 | 2024-06-10actual | — | 2025-06-10 |
| Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb SpasticityNCT05956509Change From Baseline in Wrist Modified Ashworth Scale-Bohannon (MAS-B)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Biological: ABBV-950, BOTOX · Drug: Placebo for ABBV-950 | Upper Limb Spasticity | 1 | 2024-06-02actual | — | 2024-07-01 |
| Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult ParticipantsNCT05738850Maximum Plasma Concentration (Cmax) of ABBV-932Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ABBV-932, Placebo | Generalized Anxiety Disorder (GAD), Healthy Participants | 104 | 2024-05-31actual | — | 2024-07-01 |
| A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresNCT04244175results2025-05-30Response Ratio (RRatio)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, CVL-865 | Seizures | 154 | 2024-05-21actual | — | 2025-05-30 |
| Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)NCT04026113results2024-11-26Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Linaclotide, Placebo | Functional Constipation, Irritable Bowel Syndrome With Constipation | 438 | 2024-05-20actual | — | 2024-11-26 |
| An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)NCT06126146observationalChange from Baseline in Individual Item Score in Response to Q18 "Overall, how satisfied are you with your current way of taking your medication (self injection)?" in Post-Injection Self-Injection Assessment Questionnaire (SIAQ) | — | Completed | — | Crohn's Disease | 53 | 2024-05-16actual | — | 2025-06-29 |
| A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT04497597observationalPercentage of Participants Who Achieve Remission | — | Completed | — | Rheumatoid Arthritis (RA) | 1,532 | 2024-05-15actual | — | 2025-04-13 |
| A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy AdultsNCT06054425Maximum Observed Serum Concentration (Cmax)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Risankizumab | Healthy Volunteers | 48 | 2024-05-06actual | — | 2024-05-14 |
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid LeukemiaNCT04813263observationalPercentage of Participants With ≥ Grade 3 Neutropenia of Venetoclax Regimens With Unfit Acute Myeloid Leukemia (AML) | — | Completed | — | Acute Myeloid Leukemia (AML) | 424 | 2024-04-30actual | — | 2025-04-27 |
| A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart ReviewNCT06362031observationalOverall Survival (OS) | — | Withdrawnsponsor's stated reason: Strategic considerations | — | Acute Myeloid Leukemia | 0 | 2024-04-30 | — | 2024-04-12 |
| An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World PracticeNCT05327920observationalPercentage of Participants Achieving 28-Joint Disease Activity Score (DAS28) C-reactive protein (CRP) Remission following initiation of treatment with Upadacitinib | — | Completed | — | Rheumatoid Arthritis | 93 | 2024-04-22actual | — | 2025-03-14 |
| A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose AdministrationNCT06278766Number of Participants with Adverse Events (AEs)Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-552 | Healthy Volunteer | 8 | 2024-04-19actual | — | 2024-04-29 |
| A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic StrokeNCT04309474results2025-12-22Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment PeriodRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Elezanumab, Placebo | Acute Ischemic Stroke | 121 | 2024-04-18actual | — | 2025-12-22 |
| A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United KingdomNCT05555979observationalNumber of Participants with a Change in Chronic Lymphocytic Leukemia (CLL) Symptoms | — | Completed | — | Chronic Lymphocytic Leukemia | 56 | 2024-04-10actual | — | 2025-06-29 |
| Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar LinesNCT06151561Percentage of participants with a >= 2-grade improvement from baseline on the Facial Wrinkle Scale with Asian (FWS-A) Guide according to investigator assessment of Glabellar Lines (GL) severity at maximum frown, at any timepoint through Day 7Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AGN-151586, Placebo | Moderate to Severe Glabellar Lines | 24 | 2024-04-03actual | — | 2026-06-26 |
| Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated PainNCT04630990observationalChange in Dysmenorrhea (DYS), According to Patient Reported 11-Point Numeric Rating Scale (NRS) | — | Completed | — | Endometriosis | 117 | 2024-03-26actual | — | 2025-04-01 |
| Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer MetastasisNCT04807972Phase 1b: Percentage of participants experiencing Adverse EventsRandomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-927, Budiglimab, modified FOLFIRINOX | Pancreatic Cancer | 40 | 2024-03-25actual | — | 2025-01-07 |
| A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisNCT05601882results2025-02-14Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Upadacitinib | Atopic Dermatitis | 920 | 2024-03-19actual | — | 2025-02-14 |
| Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) SymptomsNCT04949828observationalChange in Score of EPI Symptoms Domain Using an EPI Patient-Reported Outcomes Questionnaire | — | Completed | Drug: CREON | Chronic Pancreatitis | 63 | 2024-02-29actual | — | 2024-03-28 |
| Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese ParticipantsNCT06067568Maximum Observed Serum Concentration (Cmax) of LutikizumabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Lutikizumab Dose A, Lutikizumab Dose B | Healthy Volunteers | 50 | 2024-02-26actual | — | 2024-03-15 |
| Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult VolunteersNCT05892757Number of Participants Experiencing Adverse EventsNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Atogepant, Ubrogepant | Healthy Volunteers | 24 | 2024-02-22actual | — | 2024-03-12 |
| A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsNCT04435600results2025-05-20Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Risankizumab, Ustekinumab | Psoriasis | 139 | 2024-02-12actual | — | 2025-05-20 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell ArteritisNCT03725202results2025-03-07Percentage of Participants Achieving Sustained Remission at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Upadacitinib, Corticosteroid (CS) · Other: Placebo | Giant Cell Arteritis (GCA) | 429 | 2024-02-06actual | — | 2026-02-24 |
| Juvenile Idiopathic Arthritis (JIA) RegistryNCT00783510observationalIncidence of Serious Adverse Events (SAEs) | — | Completed | Biological: adalimumab · Drug: Methotrexate | Juvenile Idiopathic Arthritis, JIA | 849 | 2024-02-01actual | — | 2025-02-04 |
| An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid ArthritisNCT05170646observationalPercentage of Participants Achieving 28-Joint Disease Activity Score (DAS28) C-reactive protein (CRP) Clinical Remission | — | Completed | — | Rheumatoid Arthritis | 97 | 2024-01-31actual | — | 2025-04-29 |
| Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)NCT04542499results2025-03-25Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tavapadon, Placebo | Parkinson Disease | 507 | 2024-01-29actual | — | 2025-04-04 |
| A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung CancerNCT03639194Number of Participants With Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-011, Budigalimab | Small Cell Lung Cancer | 132 | 2024-01-25actual | — | 2024-02-09 |
| A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease StateNCT04451772results2025-01-14Number of Participants With Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib | Systemic Lupus Erythematosus (SLE) | 185 | 2024-01-03actual | — | 2025-01-14 |
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSANCT02814916results2024-09-19Shift From Baseline in Distortion Product Otoacoustic Emission at TOC VisitRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin | Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections | 199 | 2024-01-01actual | — | 2024-09-19 |
| A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction CentersNCT04366973observationalPercentage of participants with and without Hepatitis C Virus (HCV) treatment prescribed at end of the inclusion visit. | — | Completed | — | Hepatitis C Virus (HCV) | 95 | 2023-12-31actual | — | 2024-02-01 |
| Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life ConditionsNCT02738125observationalTime to loss of clinical benefit | — | Completed | — | Ulcerative Colitis (UC) | 265 | 2023-12-15actual | — | 2024-12-31 |
| A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )NCT03047395results2024-12-11Number of Participants With Serious Adverse Events and Non-Serious Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: risankizumab | Psoriasis | 2,170 | 2023-11-29actual | — | 2024-12-11 |
| A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart ReviewNCT05444972observationalTime from Diagnosis of Myelofibrosis (MF) to Initial Treatment | — | Completed | — | Myelofibrosis | 998 | 2023-11-14actual | — | 2023-12-11 |
| A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy VolunteersNCT05895266Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-903, Midazolam | Healthy Volunteer | 24 | 2023-11-02actual | — | 2023-11-09 |
| A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese ParticipantsNCT06009237Maximum observed plasma concentration (Cmax) of ABBV-903Randomized · Quadruple-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-903, Placebo for ABBV-903 | Healthy Volunteers | 24 | 2023-10-30actual | — | 2023-11-13 |
| A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy AdultsNCT05691699Maximum Observed Plasma Concentration (Cmax)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ABBV-903, Placebo for ABBV-903, Itraconazole | Healthy Volunteer | 104 | 2023-10-23actual | — | 2023-10-30 |
| A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose AdministrationNCT05995366Maximum observed concentration (Cmax) of ABBV-903Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-903 | Healthy Volunteer | 7 | 2023-10-13actual | — | 2023-10-26 |
| A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult ParticipantsNCT05878067results2024-10-15Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) ScoreOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ABBV-444 | Dry Eye Syndrome | 40 | 2023-10-06actual | — | 2024-10-15 |
| A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® InjectionsNCT05647551Change from baseline in the overall score of the participant's FACE-Q™ Satisfaction with Eyes with JUVÉDERM fillers and BOTOX/VISTABELOpen-label · Treatment | Phase 4 | Completed | Drug: BOTOX®/VISTABEL® · Device: Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine | Facial Corrections, Facial Lines | 73 | 2023-10-05actual | — | 2024-10-03 |
| RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)NCT04832724RGX-314 target protein concentration in aqueous humorNon-randomized · Open-label · Treatment | Phase 2 | Completed | Genetic: RGX-314 | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 60 | 2023-10-02actual | — | 2024-09-05 |
| Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)NCT04721002observationalPercentage of Participants With t(11;14) Status by Fluorescence In Situ Hybridization (FISH) Analysis of Bone Marrow Plasma Cells | — | Completed | — | Multiple Myeloma (MM) | 514 | 2023-09-30actual | — | 2023-10-18 |
| Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult VolunteersNCT05909553Number of Participants Experiencing Adverse EventsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Venetoclax | Healthy Volunteers | 15 | 2023-09-22actual | — | 2023-12-01 |
| Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic DermatitisNCT04195698results2025-01-09Number of Participants With Treatment-Emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Upadacitinib | Atopic Dermatitis | 475 | 2023-09-11actual | — | 2025-01-09 |
| Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic BladderNCT01192568results2024-09-04Change From Baseline in Percent of Catheterizations Without a Leaking Accident at Week 6Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Oxybutynin, Placebo | Overactive Detrusor, Neurogenic Bladder | 52 | 2023-08-29actual | — | 2024-09-04 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus InfectionNCT04913610results2024-09-19Part 1: Percentage of Live Female Adult Worms Without Wolbachia at Month 6 as Assessed By Immunohistology of NodulesRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-4083, Placebo for ABBV-4083, Albendazole, Placebo for Albendazole | Onchocerciasis | 153 | 2023-08-29actual | — | 2024-09-19 |
| A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma ProminenceNCT05134649results2024-12-05Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: OnabotulinumtoxinA | Platysma Prominence | 292 | 2023-08-18actual | — | 2024-12-05 |
| Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)NCT04554966Incidence of Study Drug-Related Grade 3 or Higher Adverse Events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ABBV-382, ABBV-382, Placebo for ABBV-382 | Human Immunodeficiency Virus (HIV) | 54 | 2023-08-14actual | — | 2024-03-04 |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisNCT04480086Percentage of Participants With Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Mivebresib, Navitoclax, Ruxolitinib | Myelofibrosis (MF) | 1 | 2023-07-28actual | — | 2023-08-29 |
| A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic ArthritisNCT04758117observationalPercentage of Participants Receiving Upadacitinib who Attain Minimal Disease Activity (MDA) | — | Completed | — | Psoriatic Arthritis | 394 | 2023-07-26actual | — | 2024-07-17 |
| A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154NCT04972968results2024-10-15Time to FlareRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-154, Placebo, Glucocorticoid | Polymyalgia Rheumatica | 181 | 2023-07-24actual | — | 2024-10-15 |
| An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New DrugsNCT03740230observationalPercentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) | — | Completed | — | Hepatitis C | 3,134 | 2023-07-21actual | — | 2024-07-19 |
| A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's DiseaseNCT05068284results2024-10-03Percentage of Participants Achieving Endoscopic Response Per Simple Endoscopic Score for Crohn's Disease (SES-CD)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-154, Placebo, ABBV-154, Placebo | Crohn's Disease | 176 | 2023-07-20actual | — | 2024-10-03 |
| Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With CreonNCT05069597results2024-07-23Mean Change in Total Symptom Score (TSS) From Day 1 (Baseline) to Days 8, 15, 29, and 85Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: CREON | Cystic Fibrosis, Chronic Pancreatitis | 30 | 2023-07-07actual | — | 2024-07-23 |
| A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesNCT05248893Number of Participants with Adverse EventsOpen-label · Treatment | Phase 3 | Completed | Drug: AGN-151586 | Glabellar Lines | 986 | 2023-06-26actual | — | 2024-05-29 |
| A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult ParticipantsNCT05836506Number of Participants with Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-903 Tablet Form 1, ABBV-903 Tablet Form 2 | Healthy Volunteer | 24 | 2023-06-20actual | — | 2023-07-17 |
| A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma ProminenceNCT04994535results2024-08-20Number of Participants With Adverse EventsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: OnabotulinumtoxinA, Placebo | Platysma Prominence | 426 | 2023-06-14actual | — | 2024-08-20 |
| Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisNCT04853368results2024-07-16Cohorts 1 and 2: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119 | Cystic Fibrosis (CF) | 48 | 2023-06-05actual | — | 2024-07-16 |
| A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar LinesNCT05496335Percentage of Participants achieving "none" or "mild" on the Facial Wrinkle Scale (FWS) according to the investigator assessment of Glabellar Lines (GL) severity at maximum frownRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AGN-151586, BOTOX, Placebo | Glabellar Lines | 90 | 2023-05-30actual | — | 2026-06-26 |
| Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeNCT04912063Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) When Co-administered With Venetoclax and Azacitidine in Participants With Treatment-Naïve Acute Myeloid Leukemia (AML) Ineligible for Standard Induction TherapyNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Lemzoparlimab, Azacitidine, Venetoclax | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 40 | 2023-05-09actual | — | 2024-02-26 |
| Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar InvolvementNCT04713592results2024-06-14Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo for Risankizumab, Risankizumab | Psoriasis | 174 | 2023-04-20actual | — | 2024-06-14 |
| Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyNCT04908475results2024-04-30Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Risankizumab, Apremilast | Psoriasis | 352 | 2023-04-20actual | — | 2024-04-30 |
| Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.NCT05567029Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Risankizumab Dose A, Risankizumab Dose B | Healthy Volunteers | 198 | 2023-04-20actual | — | 2023-04-28 |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesNCT03236857Number of Participants Experiencing Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Drug: chemotherapy, venetoclax | Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma | 143 | 2023-04-19actual | — | 2023-05-22 |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisNCT04472598results2026-03-23Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo for Navitoclax, Ruxolitinib, Navitoclax | Myelofibrosis (MF) | 252 | 2023-04-13actual | — | 2026-03-23 |
| A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)NCT02966782AUCt for azacitidineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: venetoclax, azacitidine | Myelodysplastic Syndromes (MDS) | 70 | 2023-04-05actual | — | 2023-05-09 |
| Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineNCT05264129results2024-10-08Number of Participants With Adverse Events (AEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Atogepant, Ubrogepant | Episodic Migraine | 263 | 2023-04-04actual | — | 2024-10-08 |
| A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese ParticipantsNCT05686980Number of Participants With Adverse Events (AE)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-552 | Healthy Volunteers | 18 | 2023-03-30actual | — | 2023-04-06 |
| Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's DiseaseNCT05094050Maximum Observed Plasma Concentration (Cmax) of Levodopa (LD)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-951 | Parkinson's Disease | 16 | 2023-03-17actual | — | 2023-03-24 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesNCT05248867results2024-05-24Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo, AGN-151586 | Glabellar Lines | 638 | 2023-03-17actual | — | 2024-05-24 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) ExpressionNCT04209855results2024-08-01Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 453 | 2023-03-06actual | — | 2025-08-27 |
| A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1NCT04223804Number of Participants with Study Drug-Related Adverse Events Grade 3 or HigherRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ABBV-181, Placebo | Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1 | 41 | 2023-02-27actual | — | 2023-03-09 |
| Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy ParticipantsNCT05556226Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: ABBV-154 Dose Formulation A, ABBV-154 Dose Formulation B | ABBV-154 | 40 | 2023-02-17actual | — | 2023-03-13 |
| A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian FederationNCT04253314observationalOverall Survival | — | Completed | — | Acute Myeloid Leukemia (AML) | 51 | 2023-02-16actual | — | 2024-11-07 |
| Chronic Plaque Psoriasis (Ps) RegistryNCT00799877observationalIncidence of Serious Adverse Events | — | Completed | — | Chronic Plaque Psoriasis | 6,065 | 2023-02-13actual | — | 2024-03-15 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar LinesNCT05248880results2026-02-18Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: AGN-151586, Placebo | Glabellar Lines | 309 | 2023-02-01actual | — | 2026-02-18 |
| A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal MenNCT03518034results2024-03-13Time From Randomization to the First Component Event of Major Adverse Cardiac Event (MACE): Number and Percentage of Participants With an EventRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: AndroGel®, Placebo | Hypogonadism, Cardiovascular Diseases | 5,246 | 2023-01-19actual | — | 2024-03-13 |
| Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental VitiligoNCT04927975results2024-10-08Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Upadacitinib, Placebo | Non-Segmental Vitiligo | 185 | 2023-01-13actual | — | 2024-10-08 |
| Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersNCT04804254Percentage of Participants With Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-623, ABBV-992 | B-cell Lymphoma | 5 | 2023-01-11actual | — | 2023-02-03 |
| A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and NavocaftorNCT05538585Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Galicaftor, Navocaftor | Healthy Volunteers | 24 | 2022-12-21actual | — | 2023-01-17 |
| A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma ProminenceNCT04949399results2024-11-20Number of Participants With Adverse EventsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: OnabotulinumtoxinA, Placebo | Platysma Prominence | 408 | 2022-12-20actual | — | 2024-11-20 |
| Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With PresbyopiaNCT04403763results2024-02-06Stage 1: Number of Participants Experiencing a Treatment Emergent Adverse Event After Single Administration of AGN-241622Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Strategic considerations | Drug: AGN-241622, Vehicle | Presbyopia | 80 | 2022-12-05actual | — | 2024-02-06 |
| A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT03484520Tmax of VenetoclaxNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Venetoclax, Dinaciclib | Cancer - Acute Myeloid Leukemia | 48 | 2022-12-01actual | — | 2022-12-30 |
| A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe PsoriasisNCT05044234results2023-11-29Percentage of Participants Achieving 75% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 75) at Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Company Decision | Drug: Cedirogant, Placebo | Psoriasis | 156 | 2022-11-30actual | — | 2023-11-29 |
| A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic FibrosisNCT05530278Maximum Plasma Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Galicaftor, ABBV-576, Navocaftor, Midazolam | Healthy Volunteers | 24 | 2022-11-29actual | — | 2023-02-21 |
| Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar PustulosisNCT04451720Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Risankizumab, Placebo | Palmoplantar Pustulosis (PPP) | 119 | 2022-11-21actual | — | 2022-12-05 |
| BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle ProminenceNCT04073303results2025-05-06Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Botulinum Toxin Type A · Other: Placebo | Masseter Muscle Prominence | 377 | 2022-11-10actual | — | 2025-05-06 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisNCT03398148results2025-01-16Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: risankizumab IV, placebo for risankizumab, risankizumab SC | Ulcerative Colitis (UC) | 1,558 | 2022-11-09actual | — | 2025-01-16 |
| A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic ImpairmentNCT05376839Maximum Observed Plasma Concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Cedirogant | Hepatic Impairment | 6 | 2022-11-08actual | — | 2022-12-08 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT04196283Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181 | Advanced Solid Tumors Cancer | 30 | 2022-10-27actual | — | 2023-02-27 |
| A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)NCT04198415observationalNumber of Participants With Adverse Events | — | Completed | — | Cancer, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) | 4 | 2022-10-21actual | — | 2023-10-19 |
| A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseNCT04254783Maximum Observed Plasma Concentration (Cmax) of MidazolamOpen-label · Treatment | Phase 1 | Completed | Drug: Risankizumab, Cytochrome P450 (CYP) Substrates | Ulcerative Colitis (UC), Crohn's Disease | 20 | 2022-10-14actual | — | 2024-07-01 |
| Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)NCT04799353Number of Participants Experiencing Study Drug-Related Grade 3 or Higher Adverse Events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Budigalimab, Placebo, Budigalimab, Placebo | Human Immunodeficiency Virus (HIV) | 33 | 2022-10-11actual | — | 2022-10-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19